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Abstract 
Over the last four years, a community of researchers working on Grid and High 
Performance Computing technologies started discussing the barriers and opportunities that 
grid technologies must face and exploit for the development of health-related applications. 
This interest lead to the first Healthgrid conference, held in Lyon, France, on January 16th-
17th, 2003, with the focus of creating increased awareness about the possibilities and 
advantages linked to the deployment of grid technologies in health, ultimately targeting the 
creation of a European/international grid infrastructure for health. 
The topics of this conference converged with the position of the eHealth division of the 
European Commission, whose mandate from the Lisbon Meeting was “To develop an 
intelligent environment that enables ubiquitous management of citizens’ health status, and to 
assist health professionals in coping with some major challenges, risk management and the 
integration into clinical practice of advances in health knowledge.” In this context "Health" 
involves not only clinical procedures but covers the whole range of information from 
molecular level (genetic and proteomic information) over cells and tissues, to the individual 
and finally the population level (social healthcare). Grid technology offers the opportunity to 
create a common working backbone for all different members of this large "health family" 
and will hopefully lead to an increased awareness and interoperability among disciplines. 
The first HealthGrid conference led to the creation of the Healthgrid association, a non-
profit research association legally incorporated in France but formed from the broad 
community of European researchers and institutions sharing expertise in health grids.  
After the second Healthgrid conference, held in Clermont-Ferrand on January 29th-30th, 
2004, the need for a “white paper” on the current status and prospective of health grids was 
raised. Over fifty experts from different areas of grid technologies, eHealth applications and 
the medical world were invited to contribute to the preparation of this document. 
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1. From Grid to Healthgrid: Prospects and Requirements 
1.1. RATIONALE 
Evidence-based medicine requires medical decision making to be based on sound 
knowledge of the patient combined with peer-reviewed scientific evidence, rather than 
informed guesswork and personal skill. It is also widely accepted that there is a pressing 
need to move away from manual management of patient information to digital records. 
Countries in the EU are investing heavily to establish electronic patient record systems. 
Technically the problem is one of standardization and ensuring that systems are developed 
that interface through common ‘languages’ to enable the sharing of information. 
Technology to secure the information can also be complex and expensive to deploy. 
Moreover, access to many different sources of medical data, usually geographically 
distributed, and the availability of computer-based tools that can extract the knowledge 
from that data are key requirements for providing a standard healthcare provision of high 
quality. 
Research projects in the integration of bio-medical knowledge, advances in imaging, 
development of new computational tools and the use of these technologies in diagnosis and 
treatment suggest that grid-based systems can make a significant contribution to this goal. 
The benefits of improved access are raised to a new level, not merely enhanced by 
integration over a grid. 
Grid technology has been identified as one of the key technologies to enable the 
‘European Research Area’. A major challenge is to take this technology out of the 
laboratory to the citizen, thus reaching far beyond eScience alone to eBusiness, 
eGovernment and eHealth. The benefits of grid technologies in areas involving long 
simulation processes covering a large set of experiments have been clearly proven. For 
example, High Energy Physics (HEP) is one of the main application fields of grid 
technologies [1, 2, 3]. Although grid technologies have clear potential for many applications 
(those demanding computing or storage power, dealing with geographically distributed 
information or requiring ubiquitous access), the take up of grid is slow. Reasons for this are 
the lack of adequate infrastructure, lack of users’ confidence and, most frequently, the 
shortage of applications.  
A Healthgrid should be an environment where data of medical interest can be stored, 
processed and made easily available to the different healthcare participants: researchers, 
physicians, healthcare centres and administrations, and in the long term perspective citizens. 
If such an infrastructure were to offer all necessary guarantees in terms of security, respect 
for ethics and observance of regulations, it would allow the association of post-genomic 
information and medical data, opening up the possibility for individualized healthcare.  
This white paper presents a survey of the healthgrid technologies, describing the 
current status of grid and eHealth and analysing mid-term developments and possibilities. 
There are numerous driving forces that are fostering the deployment and exploitation of the 
secure, pervasive, ubiquitous and transparent access to information and computing 
resources that grid technologies can provide. Many technical problems arising in eHealth 
(standardization of data, federation of databases, content-based knowledge extraction, and 
management of personal data) can be solved with the use of grid technologies. However, 
there are many barriers to overcome. The paper considers the procedures from other grid 
disciplines such as High Energy Physics or numerical simulation and discusses the 
differences with respect to healthcare, with the intention of outlining a path forward towards 
the successful deployment of grid technologies for eHealth and ultimately the creation of a 
Healthgrid. 
1.2. INTRODUCTION TO HEALTHGRID 
1.2.1. The European Health Sector 
eHealth deals with the use of Information and Communication Technologies (ICT) to 
develop an intelligent environment that enables ubiquitous management of citizens’ health 
status, assists health professionals in coping with some major challenges or integrates the 
advances in health knowledge into clinical practice. 
Many eHealth applications have been developed for dealing with information 
management and procedural challenges of current healthcare. eHealth is not only a good 
strategy for improving healthcare quality, but also a good business. The eHealth or Health 
Telematics sector is becoming the third industrial pillar of healthcare after the 
pharmaceutical and the medical imaging device industries. It is estimated that health 
expenditure on ICT systems and services would rise from 1% to 5% by 2010 [10], there are 
more than 1,500 health care sites on the Internet today and eHealth retailers predict 
revenues ranging from $22B to $348B (US) by the year 2004. Health care is the second 
most frequently searched topic on the Internet [11]. 
Service-based applications in eHealth are an important issue in general business. 
Application Service Provision (ASP) hosting, for example, makes it possible for service 
providers to specialize in installing and maintaining applications and services for their 
subscribing customers. ASP shifts the burden of hardware infrastructure to the providers 
and frees customers who only need an Internet browser to access the software. The general 
advantages of ASP, such as staff and resource specialization, broad marketability or 
scalable investment are complemented by the situation within the health sector: the 
healthcare market is fragmented, as many people use proprietary systems; many processes 
are tedious and could be better streamlined; and healthcare organizations have 
comparatively old legacy computer systems and less ICT staff than other sectors. However, 
there are some disadvantages. The ownership of mission-critical client functions is much 
more important in the case of healthcare. Moreover, health records persist over long time-
frames and thus require long-term storage, subject to strict legal requirements on data 
protection and security. High service-level provision is also critical in healthcare, while 
medical information can require high bandwidth connections to meet minimum delay 
requirements.  Nevertheless, electronic processing of medical data has opened many 
possibilities for improving medical tasks such as diagnosis, surgical planning or therapy, 
both in daily clinical practice and clinical research.  
Linking databases with medical information is necessary, but it is only part of the 
solution. Further processing of the information to extract knowledge is a must, since the 
sheer volume of information makes it impossible to search directly. Data mining can 
provide the means to analyse relevant information and perform population-oriented health 
studies 
Electronic processing of medical data is at different stages of evolution in different places 
and even in different departments. Hospital Information Systems are widely used for in-
patient management. Laboratory and image diagnosis departments have an important degree 
of electronic management of patient data. The adoption of these technologies in Primary 
Care is less advanced. However, the main challenge is the so-called Electronic Patient 
Record (EPR). EPR promises coherent access to and management of the complete patient 
information of an individual or a population. There is a great deal of effort already invested 
to achieve this aim, including on standardization. 
Security is the most important issue. Personal data (any piece of information in which 
its owner can be identified, either directly or in combination with information that is 
available or can otherwise located) is confidential, so access to the information must be 
performed only by authorized and authenticated persons, and data must be encrypted to 
guarantee its confidentiality and integrity. Moreover, electronic archiving of personal data is 
strictly regulated by European and national laws. Pervasive access and fault tolerance are 
other important aspects, since medical practice requires round-the-clock availability.  
Medical information is voluminous and dispersed. Large resources are needed to store 
patient records comprising images, bio-signals, plain text, videos, photographs or other 
forms of digital data. Moreover, healthcare provision structure is distributed and 
information is not consolidated among hospitals, primary care and casualty departments. 
Linking federated databases requires computing effort and complex structures. Medical 
information is far from ‘standard’.  It is often stored in mutually incompatible formats and 
standards are neither complete nor universally accepted. Even the use of a standard protocol 
may not imply that independently derived data representing a specific ‘the same’ piece of 
information will be identical. Tuning and quality of equipment and expertise of the staff all 
affect the final results. 
In the medium term, it is reasonable to expect that most of the services in healthcare 
will use computer-based resources to store, process and share patient information. 
Technologies are converging to a mature status and high-bandwidth communication 
networks are being deployed among healthcare centres throughout Europe, although, of 
course, there are still differentials between member states. A new key enabling technology 
is the grid. 
1.2.2. Introduction to Grid 
Grid computing aims at the provision of a global ICT infrastructure that will enable a 
coordinated, flexible, and secure sharing of diverse resources, including computers, 
applications, data, storage, networks, and scientific instruments across dynamic and 
geographically dispersed organizations and communities (known collectively as Virtual 
Organizations or VOs). Grid technologies promise to change the way organizations tackle 
complex problems by offering unprecedented opportunities for resource sharing and 
collaboration. Just as the World Wide Web transformed the way we exchange information, 
the grid concept takes parallel and distributed computing a major step forward towards what 
is sometimes called ‘utility computing’, providing a unified, resilient, and transparent 
infrastructure, available on demand, in order to solve increasingly complex problems. 
Grids may be classified into computational grids, data/information/knowledge grids, 
and collaborative grids. The goal of a computational grid is to create a virtual 
supercomputer, which dynamically aggregates the power of a large number of individual 
computers in order to provide a platform for advanced high-performance and/or high-
throughput applications that could not be tackled by a single system. Data grids, on the 
other hand, focus on the sharing of vast quantities of data. Information and knowledge grids 
extend the capabilities of data grids by providing support for data categorization, 
information discovery, ontologies, and knowledge sharing and reuse. Collaborative grids 
establish a virtual environment, which enables geographically dispersed individuals or 
groups of people to cooperate, as they pursue common goals. Collaborative grid 
technologies also enable the realization of virtual laboratories or the remote control and 
management of equipment, sensors, and instruments.  
From the original experiments investigating possibilities offered by broadband 
networks, grid technologies have entered into a phase where production capabilities are 
available, e.g. NASA’s Information Power Grid, CERN’s DataGrid, or NSF’s TeraGrid, to 
name a few. However, the vision of large scale resource sharing has not yet become a 
reality in many areas. This can be attributed mainly to the lack of commonly accepted 
standards, as well as to the diversity and fragmentation of available grid middleware, tools 
and services. The Global Grid Forum (GGF), with participants from industry, research, and 
academia is the main body driving global standardization efforts for grid services, protocols, 
and interfaces.  
According to a recent survey of twenty European grid projects, the most widely used 
middleware is the Globus toolkit followed by Unicore. Over the last two years, however, 
the Globus toolkit, which has been originally designed for the needs of High Performance 
Computing (HPC) resource sharing in the academic community, has undergone a significant 
shift towards the adoption of a service-oriented paradigm, and the increasing support for 
and utilization of commercial Web Services technologies. The Open Grid Services 
Architecture (OGSA) was a first effort in bringing grid technologies and Web Services 
together. The recent decision of GGF to base the implementation of OGSA on the 
forthcoming Web Services Resource Framework (WSRF), currently standardized by OASIS, 
is a further significant step in this direction and will allow the utilization of standard Web 
Services technologies, which enjoy large scale industry support, for grid computing. 
Future developments of grid technologies will be characterized by a full adoption of the 
service-oriented paradigm and Web Services technologies, a complete virtualization of 
resources and services, and the increased utilization of semantic information and ontologies 
(cf. Semantic Grid). Significant efforts will have to be undertaken in order to provide 
appropriate high-level tools and environments that hide the complexity and reduce the costs 
of grid application development. The availability and adoption of advanced security 
standards, support for Quality of Service and the establishment of associated grid business 
models and processes, will be pre-requisites for large scale adoption of grid technologies.  
1.2.3. HealthGrids 
Healthgrids are grid infrastructures comprising applications, services or middleware 
components that deal with the specific problems arising in the processing of biomedical 
data. Resources in healthgrids are databases, computing power, medical expertise and even 
medical devices. Healthgrids are thus closely related to eHealth.  
Although the ultimate goal for eHealth in Europe would be the creation of a single 
healthgrid, i.e. a grid comprising all eHealth resources, naturally including security and 
authorization features to handle subsidiarity of independent nodes of the healthgrid, the 
development path will mostly likely include a set of specific healthgrids with perhaps 
rudimentary inter-grid interaction/interoperational capabilities.   
The future [13] evolution of grid technologies addresses most precisely problems that 
are very appropriate for healthcare. Healthgrid applications are oriented to both the 
individualized healthcare and the epidemiology analysis. Individualized healthcare is 
improved by the efficient and secure combination of immediate availability of personal 
clinical information and widespread availability of advanced services for diagnostic and 
therapy. Epidemiology healthgrids combine the information from a wide population to 
extract the knowledge that can lead to the discovery of new correlations between symptoms, 
diseases, genetic features or any other clinical data. 
The following issues are identified as key features of healthgrids: 
? Healthgrids are more closely related to data, but hospitals are reluctant to let 
information flow outside hospital bounds. For a large-scale deployment of healthgrids, 
and thus for opening an attractive business, it is important to leverage security up to a 
trustworthy level of confidence that could release a generalized access to data from the 
outside (see also below). Although data storage remains the responsibility of the 
hospital, many business opportunities can arise from data sharing and processing 
applications. Federation of databases requires computing effort and complex structures. 
? Management of distributed databases and data mining capabilities are important tools 
for many biomedical applications in fields such epidemiology, drug design or even 
diagnosis. Expert system services running on the grid must be able to interrogate large 
distributed databases to extract such knowledge as may lead to the early detection of 
new sources of diseases, risk populations, evolution of diseases or suitable proteins to 
fight against specific diseases.  
? Security in grid infrastructures is currently adequate for research platforms, but it must 
be improved in the future to ensure privacy of data in real healthgrids. Encrypted 
transmission and storage is not sufficient, integrity of data and automatic pseudo-
nymization or anonymization services must be provided to guarantee that data is 
complete and reliable and privacy leakages can not appear due to unattended use of the 
resources. Biomedical information must be carefully managed to avoid privacy 
leakages. Failure on privacy in biomedical personal information causes irreparable 
damage, since there is no way to retrieve the situation. Secure transmission must be 
complemented with secure storage with strictly controlled authenticated and authorized 
access.  Automatic pseudo/anonymization is necessary for a production stage. 
? Robustness and fault tolerance of grids fits very well to the needs for ‘always on’ 
medical applications. Grid technologies can ease the access to replicated resources and 
information, just requiring the user to have a permanent Internet connection. 
? Research communities in biocomputing or biomodelling and simulation have a strong 
need for resources that can be provided through the grid. Compliance with medical 
information standards is necessary for accessing large databases. There are many 
consolidated and emerging standards that must be taken into account. Complex and 
multimedia information such as images, signals, videos, etc. is clearly a target for grid 
and is more sensitive to data formats. 
? Finally, flexibility is needed for the control of VOs at a large level. The management of 
resources should be more precise and dynamic, depending on many criteria such as 
urgency, users’ authorization or other administrative policies. 
Today most grid applications for health follow the classic high-throughput approach. 
Numerical simulation of organs obtained from patients’ data [14, 15] is used to aid 
understanding and to improve the design of medical devices. Patient-customized approaches 
can be found at research level in areas such as radiotherapy, cranio-facial surgery or 
neurosurgery.  
Other areas of application deal with large-scale information processing, such as medical 
imaging. Breast cancer imaging has been the focus of several successful grid projects [16, 
17] and eHealth projects suitable to migrate to grid [18]. These efforts have concentrated on 
federating and sharing the data and the implementation of semi-automatic processing tools 
that could improve the sensitivity and specificity of breast cancer screening programs. 
Much effort has been invested to reduce the information needed to be exchanged and to 
protect privacy of the information. 
The concept of a patient-centric grid for health has also been explored [19]. The main 
aim of this approach is to make the information available to the whole health community 
(patient, relatives, physicians, nursery), considering access rights and language limitations.  
Bioinformatics is the area where grid technologies are more straightforwardly 
introduced. The main challenge faced by bioinformatics is the development and 
maintenance of an infrastructure for the storage, access, transfer and simulation of 
biomedical information and processes. Current efforts on biocomputation [20] are coherent 
with the aims of grid technologies. Work on the integration of clinical and genetic 
distributed information, and the development of standard vocabularies, will ease the sharing 
of data and resources. 
1.3. DEFICITS, OPPORTUNITIES AND REQUIREMENTS FOR INDUSTRY 
Grid technology is still a ‘moving target’. The rapid evolution of platforms and versions 
leads to major difficulties in the development of applications to a production stage. Industry 
has to define and exploit business models on the grid, but it needs more stability and 
standardization on grid infrastructures before it can develop viable business models. Indeed, 
current grid middleware lacks several components that would be necessary for business 
exploitation: 
? Grid middleware lacks reliable and complete accounting services that can clearly 
identify providers, consumers and resource usage in a scenario in which a wide range 
of heterogeneous resources, owned by different entities, are shared.  The whole 
economics of the grid is still to be worked out. 
? Current efforts at robustness and fault tolerance have improved middleware reliability, 
crucial for exploitation in healthcare applications, but it is still not at a production level. 
? Security and privacy models for the grid are not adequate for applications that can be 
certified by end users and health authorities. 
? Reliable benchmarking must be performed to certify that all components perform with 
the quality of service and robustness that healthcare applications require. Middleware 
certification is even more important in healthcare applications, taking account of 
possible impact on patient health, and on legal and ethical considerations. 
? Grid exploitation may encounter a serious problem in the use of software licences. 
Current software licenses usually prevent its use in grid environments in which the 
computers and the users are not clearly defined. New licence models will appear with 
the development and new business models. Until then, successful applications should 
better focus on the exploitation of own or public licence software. 
? Before developing business-relevant applications, there is a clear need of a production 
infrastructure in which applications can be run. Many services can be implemented 
and tested and deployed for validation. Validation of healthcare applications can then 
be undertaken on such a platform, although final exploitation can be deployed on 
separate resources. 
There are at least three scenarios in which healthgrid technologies can be successful 
from a business point of view: 
? Consolidation of resources: Integral solutions for applications, data and resources at 
centre and region are needed. (Current distributed database technologies do not yet 
offer the level of interoperability or the capability of providing other resources, apart 
from data, to make this a reality.) 
? Efficiency leveraging: Ideal applications from the business point of view are those 
requiring large peak resources followed of inactivity periods.  
? Reduction of production costs in applications where the return on investment is low 
but the social impact can be high. Joint public-private consortia may succeed in 
healthcare goals, such as rare disease drug discovery, that do not offer economic profit 
but may benefit significant populations. Providing resources for in-silico 
experimentation may stimulate the discovery of affordable, effective drugs for 
neglected diseases. 
There is a long way to go before exploitation, and industry should assist and guide 
research on healthgrids in order to profit from reliable and interesting results. 
1.3.1. The pharmaceutical Industry 
The convergence of biotechnology and ICT are providing novel drug development 
methods, as a consequence of which pharmaceutical industry requires enormous amounts of 
computing capacity to model, discover and test interactions of drugs with receptors, and 
thus to decide which should be synthesized and tested. 
Drugs that come to market are the results of several years of research. There is a need 
to accelerate the development process and reduce time to market for new drugs.  One way 
this can be done is by increasing the number of calculations processed for docking analysis. 
Computation with virtual compounds produces a large volume of information which is hard 
to analyse both in terms of time and cost. These results must be stored for further analysis, 
creating the need for mechanisms to share securely and privately the information among 
federated databases.  
In fact, there is an overload of information, but there is a lack of interoperability 
between different applications and data sources. Current tools cannot handle the results in 
an effective way, nor do they extract enough knowledge. This means that there is a lot of 
wasted information and unused results.  Collaboration between scientists and researchers 
from industry is crucial for success in the pharmaceutical industry. 
The next step in drug development is to integrate phenotype with genotype information 
and environmental factors, leading to ‘personalized’ drugs, leads to the need for on-demand 
analysis, requiring more resources and tools. 
1.3.2. Medical Information Technologies Industry 
Most important challenge in medical IT is the need to reach the maximum degree of 
interoperability, seamless access and processing of distributed electronic medical 
information. This challenge, based on the electronic patient record, requires the interaction 
of industry, research and standardization bodies.  
These aims are not achievable solely through the integration of distributed databases. 
First, not all the information is comparable or compatible, not only in terms of format, but 
also due to differences in procedures, devices, human intervention or other factors. 
Federation of data must be achieved at a semantic level for interoperability to become a 
reality. Secondly, much medical information is not currently processed electronically. Vital 
signs, perception tests and laboratory analyses are usually captured and stored, even in 
digital form, but not available for further processing through lack of connectivity or 
incompatibility. Interfaces for equipment and storage formats are currently being developed 
and standardized, but take-up is slow. 
The integrated electronic patient record will require a significant increase in resources 
for storage and processing, so that clinical institutions will certainly have to consider 
sharing computing services. Interoperability among devices will be a strict necessity. New 
services may then be made available on this infrastructure, including clinical aid 
applications, such as computer aided diagnosis, image processing, vital sign feature 
extraction, clinical output evaluation or even simulation. 
1.4. DEFICITS, OPPORTUNITIES AND REQUIREMENTS FOR HEALTHCARE AND 
MEDICAL RESEARCH 
The situation in ‘routine’ healthcare is very different from that of medical research. The 
main target for healthcare-oriented grids is to access large amounts of data securely and 
efficiently, with occasional need for high processing power. Medical research however 
deals with a wider set of issues. Computing resources, knowledge extraction from very 
large databases and means for solving grand-challenge problems are important concerns in 
different applications. 
Biocomputing medical applications are one family of “killer applications” for 
biomedical grid research. The maturity of genetics and biomedical technologies brings them 
closer to medicine, and grand-challenge computing problems of biocomputing are currently 
being migrated to grid [20]. Biomedical modelling and simulation is another important 
arena for grid applications. Biomedical models are highly coupled, involve complex physics 
and require intensive numeric computing. Coupling the models is essential to achieve a 
realistic simulation that could give useful feedback to medical science and medical 
instrument technology. The long-term aim of the “virtual human being” can only be 
technologically feasible with very large computing resources. National e-science 
infrastructures may not be sufficient for such a large goal. 
Healthcare grids’ key issue is to be provided with the proper services for querying, 
storing and retrieving multimedia medical data from a data grid. Privacy Enhancing 
Techniques must be considered to allow medical data access from outside the borders of the 
medical database holders. Coordination with EPR initiatives is fundamental to avoid 
replication of effort and to ensure the applicability of results. Connection to medical 
information systems such as Hospital Information Systems, Picture Archiving Computer 
Systems, Radiology, Laboratory and Primary Care Information Systems will be very 
important for access to data, while the development of libraries of services will ease the 
process of building up medically-relevant applications. 
Last but not least, the grid is an important opportunity for the spreading of knowledge 
in developing countries. Sharing medical data, procedures, services and expertise with 
research centres in those countries where these tools are not widely available may be a first 
step towards improving healthcare delivery and, at the same time, medical expertise. 
1.4.1. Medical information processing 
The ultimate goal of biomedical and health informatics is to support the continuity of 
individualized health care from prevention to rehabilitation. However, integration of 
informatics and technology tools in clinical practice has progressed far slower than expected, 
and the communication gap between clinicians and informaticians is still significant. 
The difficulties in widely implementing research results have been discussed 
extensively in recent years. Some factors arise both in research and in implementation, and 
are related to intrinsic difficulties in medical informatics, such as the complexity of 
information and organization, human factors, and diversity of cultures, especially in relation 
to financial and business aspects. For example, where specific algorithms have been 
developed and applied efficiently to a very narrow range of specific cases, extended 
validation would be necessary before use in healthcare. A broad biomedical and health 
informatics platform, enabling interconnection and integration of resources, while 
supporting evidence-based medicine and validation of research results, would thus 
contribute to the acceptance of technological developments in the medical world.  
A key point in medical informatics is the management of medical information, and the 
efficient and quality certification of information and knowledge flow between all the 
players involved in the health delivery process. Previously obtained knowledge has to be 
captured and organized in a structured form in order to be retrieved in the right context and 
in an organized manner, thus contributing both to educational and to research purposes, 
while simultaneously supporting new healthcare diagnoses and the generation of new 
medical knowledge.  
The basic strategies and scope of medical informatics has also been reconsidered in the 
context of its relationship with bioinformatics. A potential for collaboration between the 
two disciplines could involve topics such as the understanding of molecular causes of 
disease, the efficient disease management of chronically ill patients and the integration of 
clinical and genetic data. An interesting perspective is the combination of pervasive 
computing, facilitating the transmission and collection of biological data on a real-time 
basis outside a clinical setting, with the biomarkers and other indicators, resulting in a new 
phase for home care systems.  
Concluding, there is an emerging need for exchange, synthesis and ethically-sound 
application of knowledge - within a complex system of interactions among researchers and 
users, in an interdisciplinary environment - to accelerate the capture of the benefits of 
research through more effective services and products, a strengthened health care system 
and ultimately better health.  These requirements support the applicability of grid 
technologies, which provide the functional and architectural framework to facilitate such 
synergies while addressing the underlying ethical and privacy issues. 
1.4.2. Biomedical modelling 
Research in the physics of human biomedical processes has made much progress 
recently. The consolidation of accurate and complete simulation tools for many engineering 
processes has contributed to the development of biomedical models of the structural 
dynamics, fluid dynamics, chemical processes, and electric potential propagation which 
describe with high degree of accuracy the physics of many organs and tissues.  
All these models are generally applied to restricted small areas or do not reach the 
desired accuracy due to the large memory requirements that fine meshing for numerical 
analysis requires. Moreover, the complexity of human biomedical models lies on the high 
degree of coupling among the chemical, structural, magnetic and electric processes. This 
complexity requires further improvement of biomedical models and use of unprecedented 
computing and memory resources. 
Thus, the evolution towards the “virtual human” model is a major long-term aim of 
biomedical computing. Tackling such a problem requires the close cooperation of many 
groups, sharing computing resources, models and data. Accurate medical models are not 
freely available, and usually represent the most valuable capital of a research centre. Means 
for cooperating without compromising Intellectual Property Rights (IPR) are necessary. 
1.4.3. Genomics 
Genome-wide sequencing projects have been completed for many organisms, including 
Home Sapiens [4] and Mus Musculus [5]. This reversed the conventional approach to 
biomedical discovery, in which understanding a certain biological function required 
identification (and sequencing) of one or more genes involved in that function: the current 
situation is that thousands of genes have been sequenced but still wait for any functional 
information to be assigned to them.  
The fact that genes of unknown function represent over 70% of all genes, suggests that 
current comprehension of most biological and pathological processes is far from complete. 
As a consequence, new technological platforms that take advantage of the genome sequence 
information to explore gene function in a systematic way are evolving at an incredibly fast 
pace. Application of microarray technology [6] to more translational research fields, such as 
cancer research, has revealed its enormous potential as a diagnostic support tool in clinical 
management. Recent work has shown that it is possible to exploit gene expression profiling 
of tumour samples to define sets of genes (signatures) whose expression correlates, 
positively or negatively, with specific clinical features, such as metastasis-free survival in 
breast cancer [8], and response to therapy [7]. Other types of massive datasets currently 
generated in genomics projects include: protein expression levels, measured by proteomic 
screening; protein-protein interaction datasets in various organisms; protein structure data; 
genomic sequencing of additional organisms, and comparative genomics; sequence 
polymorphisms in human populations, mutational analysis in human cancer and in 
hereditary diseases; loss-of function analysis in various organisms by small interfering RNA 
(siRNA)-based approaches [9].  
As a consequence of these genomic research activities, biomedical databases are 
continually and exponentially increasing in number and size, together with bioinformatic 
tools that extract information from them. Major research laboratories (e.g. NCBI in the USA 
and EBI in Europe) collect and regularly update information. These data can be analysed 
using a web interface to a number of well-known applications (mainly data mining 
programs), that are CPU intensive and require large amounts of I/O. 
Often a data analysis process requires the pipelining of results through different 
applications. The retrieval of results from a web-based application is an awkward and error 
prone task involving ‘screen scraping’, electronically capturing the content of the screen. 
This is further complicated by the changes to web interfaces. Even though the computing 
resources dedicated to any single researcher are limited, concurrent access to the web 
applications leads to the congestion of the major resource centres. Hence, biologists prefer 
to download the database files and to process them locally.  
This has two major consequences: every single researcher has to track the database 
update process to keep his/her copy of the data up-to-date; the massive download of huge 
amounts of data worsen the performances of the web site and of the applications of the 
download centre. 
Another relevant aspect is the lack of a standardization of the published databases: 
cross-referencing of data is made difficult (if not impossible) by redundancies and 
incoherencies, there is neither standard query language, nor central management of data, 
and finally, different processing applications require the same data in different formats.  
Data quality control and, accordingly, confidence in the results obtained is poor. 
A grid infrastructure is expected to overcome many of the drawbacks of the existing 
web-based approaches to genomic data handling and mining, by offering new services such 
as the transparent access to computing resources for CPU-intensive processes which is 
important due to the high computing demand of the biomedical problems. Another 
important task is the creation and management of shared, coherent relational databases to 
resolve incoherencies and inconsistencies in the actual databases and to provide the 
infrastructure to gather data coming from genomic experiments, providing the means to 
manage replicated copies of the data files and their coordinated updating.  
Finally, database security (all aspects concerning data confidentiality), data transfer 
channel encryption and, last but not least; user authentication and authorization must be 
considered as a main requirement. 
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2. A Compelling Business Case for Healthgrid 
Although both healthcare in general and the use of IT to support the development of 
effective treatment, delivery and management of healthcare are top priorities in many 
countries, there are many areas competing for investment.  The benefits of using even basic 
IT to provide high quality information and decision support to clinicians and patients are 
intuitively very significant.  In other industries – airlines, automotive, banking, defence, and 
manufacturing – IT has underpinned productivity, quality, security and improved product 
performance for many years.  However, progress in even basic IT has been patchy and slow 
in the healthcare industry; there are few high quality, well documented business cases with 
results and very few for IT implementation at large scale.  There are even fewer cases that 
demonstrate the benefits of dramatically new IT technologies (like grid) in innovative areas 
of healthcare such as genetics, imaging, or bioinformatics.  Therefore in applying for 
funding and prioritization of resources to continue to develop healthgrid applications, I t is 
vital that a clear and highly compelling business case is created that acts on all the benefits 
levers of healthcare. 
2.1. THE GROWING IMPORTANCE OF IT IN DELIVERING EFFICIENT, HIGH 
QUALITY HEALTHCARE 
The advent of healthgrid applications, even at the research stage, coincides with a 
crucial period of investment and experimentation in IT for healthcare.   The main drivers for 
this shift in the pace and levels of investment include:  
• Increased understanding of the impact of medical errors on patient safety and the 
resulting cost of care.  IT’s basic value proposition includes the ability to regulate 
processes and scale information “written” once to many uses and contexts. 
• Demand for healthcare is outstripping resources at all levels, driven by an ageing 
population in most countries, living longer but with access to an increasingly 
sophisticated armoury of tests, surgical interventions, medications, etc.  IT has the 
power both to add to the armoury of clinical tools and to reduce costs through 
efficient operation with fewer process steps, less wasted activity (tests, 
unnecessary prescriptions, etc.) and better utilization of disparate resources 
The coincidence of growing capability in grid technology with this increase in 
investment has its drawbacks.  First, there are many strategic and investment plans being 
made at local, regional and national levels that take no account of emerging technologies 
like grid; even if the first truly useful healthgrid applications will not be ready for several 
years, this is within the planning horizons and budgeting horizons of the Public Sector.  
Secondly, as IT is introduced into everyday healthcare, custom and practice is changing on 
how care is delivered.  Such change in the clinical world is very significant – for instance 
rationalising the outpatients’ process to a single series of steps supported by sharing of 
electronic data, in all hospitals within a region, is a considerable change.  Overlaying such 
serious changes with the completely new capabilities of grid will simply add to the 
challenges.  And in healthcare, change can take time to embed – a recent study in the USA 
showed an average 17 year delay in adopting widely proven practices in healthcare. 
And are healthgrid technologies being anticipated in the many eHealth strategies being 
created around Europe?  In short, the answer is “No”.  Very few senior health managers in 
Europe understand the potential or the practicalities of healthgrid; in general, they are 
certainly not embedding their strategies with even link points to take advantage of grid in 
the future.  The risk, therefore, is that it will be even harder than it should be to take 
advantage of healthgrid capabilities over the next 5-10 years – unless the potential is 
understood quickly and strategies adapted accordingly. 
2.1.1. Measuring success – Quality, Access, Cost 
So as the business case for healthgrid is so critical, how can it be articulated in terms 
that senior health managers can understand?  One suggestion, based on the work of the 
European Commission’s eHealth Unit, is to define the benefits across three categories, 
specifically the impact on: 
• Raising the quality of care.  Here factors include the ability to make faster 
decisions or interventions; fewer medical errors; more informed decisions or 
diagnoses; 
• Improving the access of patients to care.  Sources of benefit might include the 
extension of lengthy or complex tests and diagnoses to a much larger number of 
patients through increased capacity; the provision of new tests or diagnoses that 
simply could not be made using traditional approaches at reasonable cost; 
• Reducing the cost of care.  This is a complex issue for healthgrid since it is an 
emerging technology creating opportunities for new procedures and tests that may 
initially add to short term costs; however, there may be sources of benefit from 
such short term investments leading to long term reductions in cost of care, e.g. as 
disease is identified earlier and prevented. 
It is important to recognise that rarely do these three factors appear independently – for 
instance it may be that improving the access to care via new tests also impacts the long term 
cost of treating either chronic diseases or immediate palliative care. 
Casting the benefits of healthgrid applications against these three factors has a great 
advantage in creating compelling business cases for senior health management – and 
politicians – because it allows them to see the benefit in the comprehensible terms of 
managing day to day healthcare outcomes and budgets.  Creating such resonance is critical 
to gaining priority and share of resources / budgets. 
2.2. WHY INVEST IN HEALTHGRID APPLICATIONS AND SERVICES? 
Not only does the modern healthcare management team have many choices for 
investment of their time and money in traditional sources of patient care improvement, but 
they also have a bewildering array of IT support that can be purchased. So why, in such an 
already complex, packed marketplace, should the relatively new, often untried, grid 
technologies be given any priority at all? 
2.2.1. Critical opportunities for distributed computing approaches 
Of course, not all healthcare informatics problems will be remotely suitable for a grid 
solution.  There are “sweet spot” problems where the advantages of grid approaches will 
outweigh the potential drawbacks of a relatively untried and new technology.  The 
characteristics of clinical problems that could have significant advantage from distributed 
computing-type solutions include: 
• analyses that require dynamically assembled data-sets and investigation routines; 
for instance, genetic-related investigations where the initial analysis may raise the 
need for further data sets to be added to give better, more representative results 
from analysis; 
• processes of analysis and data assembly that cross organisational boundaries, 
where the ability to distribute both the data and analysis without recall to the 
normal “data process” flows is key. Again, medical research, or in future patient-
centric analyses, are probably two areas where the utility of the grid will be 
highest; 
• huge scale analysis, that requires a scalable infrastructure to deal with the 
potentially massive quantities of data to be both assembled and analysed.  This 
leads us again to imaging and genetic analysis as potential opportunities; 
• dynamic grouping of healthcare professionals for review / analysis of diagnosis or 
research results, such that different “expert teams” can be assembled without a 
formal organisation structure (indeed, across organisation structures). Feedback 
from clinicians on existing grid health projects indicates a strong need to enhance 
collaboration on a daily basis between communities, removing their reliance on 
conferences to achieve this. 
• Further benefits may be realised through the pooling of resources, whether it be the 
sharing of training cases to enable smaller clinics to benefit from the knowledge 
available in larger hospitals, or the sharing of compute resource to reduce the local 
investment on IT. 
Therefore, in summary, there seems to be an advantage available from using grid 
approaches where the clinical problem requires a scalable, flexible infrastructure that can 
work across normal organisation and process boundaries. 
2.2.2. Impact on wider patient access to care 
The key value that grid approaches can bring to increasing patient access is to make 
possible new analyses of data, whether for individual patient care or group research, that 
traditional computing approaches cannot provide.  The principal features of problems that 
suit such approaches are those involving huge quantities of data requiring iterative, 
repetitive analyses – typically image diagnosis, genetic diagnosis are current problems with 
these features. 
2.2.3. Impact on raising the quality of care 
The application of grid technology could allow better analysis of patient data – by 
dynamically assembling data sets for comparison; by using discoverable publishing to 
improve access to previously difficult to find data; by allowing self-describing data sets to 
be more freely used, therefore raising the quality of the resulting analysis.  The areas where 
this could have greatest benefit may include rarer instances of disease diagnosis, complex 
image manipulation, and even temporal comparisons of patient information to assist with 
determining change. 
2.2.4. Impact on reducing the cost of delivering care 
From all the discussions, it seems that the main, direct advantage that healthgrid could 
provide in its application is to create a high degree of utilisation of infrastructure and 
computing power, while still allowing a very flexible, scalable infrastructure to be applied 
that could deal with dramatically varying demand.   Indirect cost advantages would derive 
from two main categories - first is the maintenance and effort put into IT, which in a grid 
solution should be, in theory at least, easier to manage since data is self-discoverable and 
infrastructures are managed in a more flexible way.  Secondly, there are all the potential 
cost savings in the delivery of care stemming from the improved quality and increased 
access to care that grid approaches offer. 
2.3. BARRIERS TO ECONOMIC, RAPID IMPLEMENTATION  
While there may be some very serious advantages to be had from applying healthgrid 
technologies to suitable problems, there remain significant barriers to implementation.  
They can be summarised into 3 main areas: 
2.3.1. Governance and accountability 
On many levels, the healthgrid does not match current governance models and tried and 
tested processes. As one example, research conducted using grid approaches does not 
necessarily have the same degree of independent scrutiny and open accountability to which 
traditional peer-reviewed research is routinely subjected. In fact, the very nature of 
dynamically assembled, self-discoverable data sets and analyses means that such scrutiny is 
probably impossible. Secondly, the entire area of trust (particularly in data) is critical to the 
widespread acceptance of grid approaches in health. This trust issue ranges from building 
diagnoses or clinical evidence on data collected, maintained and shared by organisations or 
individuals outside of the originator’s span of control to accepting that grid applications 
must be shared across organisations’ infrastructures. 
2.3.2. Quality of Service and speed 
With any distributes system, where all pieces of the infrastructure (computing devices, 
data stores and networks) are not under a single span of control, the issue of the availability 
of resources, and the maintenance and reliability of such resources, is critical.  Add to this 
reliability issue the potential contention for resources that massive data manipulation could 
experience, and the quality of service (guaranteed speed of response) could be frequently 
compromised.  There are approaches for managing this problem, but most increase the cost 
or require heavy structured governance processes. 
2.3.3. Incomplete models & technologies 
Much of the grid technology has only been applied in research fields where human 
lives do not literally depend on it or the decisions made on its output.  Before life-critical 
applications can be trusted, many more examples, pilots and controlled trials will be 
necessary. Whilst there have been significant advances in standards for the integration of 
healthcare systems, it is evident that further work is needed in order to take this to the 
dimension of ‘the big joined-up healthcare’ approach. 
2.4. IN CONCLUSION 
The healthgrid is potentially a significant addition to the armoury of tools health 
professionals and researchers can use to improve quality, increase access and reduce the 
cost of healthcare.  However, significant progress is required on the governance, quality of 
service and operational models for grid technology before it can become a widespread tool 
in daily use. 
 
 
3. Medical Imaging and Medical Image Processing 
3.1. MEDICAL IMAGING  
Medical diagnosis and intervention increasingly relies upon images, of which there is a 
growing range available to the clinician: X ray (increasingly digital, though still 
overwhelmingly film-based), ultrasound, MRI, CT, PET scans etc. This trend will increase 
as high bandwidth systems for picture archiving and communications are installed in large 
numbers of hospitals (currently, primarily in large teaching hospitals). More than patient 
data, the medical images by far represent the major amount of information collected for 
medical data. However, medical images are not sufficient by themselves as they may need 
to be interpreted and analysed in the context of the patient’s medical record (that is the 
metadata associated with the images).  
There are a number of factors that make patient management based on medical images 
particularly difficult. Medical data are naturally distributed over a number of acquisition 
sites. Physicians most often have no way to access all the medical records across all of their 
patients. Patient images often represent very large quantities of data (e.g. 3-D images, time 
sequences, multiple imaging protocols) with complex structure (clinically and 
epidemiologically significant signs are subtle including patient age, diet, lifestyle and 
clinical history, image acquisition parameters, and anatomical/physiological variations). In 
many cases, no single imaging modality suffices, since there are many parameters that 
affect the appearance of an image and complementary information is captured by different 
physical acquisition systems.  
Medical data are used in diagnosis, continuing care, and therapy planning. For 
diagnosis, medical images acquired in a medical centre are usually visualised and 
interpreted immediately after the acquisition by the radiologist before being sent (often on 
films) to a physician for second viewing. These two readings normally take place in 
different offices and possibly even in different sites. For therapy follow-up, even more 
clinicians may be involved as images taken at different times may have been acquired in 
different radiology centres and several physicians may need to read them. For therapy 
planning and assisted intervention, images also need to be accessible from the intervention 
room. 
Picture Archiving and Communication Systems (PACS) deployed in hospitals today 
address some of the challenges related to medical data management. However they suffer 
many limitations: 
• Often they are disconnected from the Radiological Information System (RIS) 
carrying the medical records. 
• They are often proprietary solutions of medical imaging companies and no open 
standards exist to ease communication between different PACS. 
• They are usually limited to data management inside one health unit (one hospital or 
at best a federation of hospitals) and are not scalable on a national or international 
scale. 
Manipulating medical data on a large scale also raises the problems of security and 
confidentiality of personal data. Grid technologies are expected to ease the design of 
distributed medical information systems in a secured environment. Although grids cannot 
by themselves resolve the problem of heterogeneity in data formats and communication 
protocols, they are expected to motivate the establishment of standards in this field. 
3.1.1. From medical data acquisition to medical data storage and archiving 
Although most recent medical imaging equipment produces digital images, the long 
term archiving of data is often performed on film only. Medical images represent enormous 
amounts of data: a single image can range from a few megabytes to one gigabyte or more. 
The total amount of digital images produced in Europe thus probably exceeds 1000 
petabytes each year. The legal aspects concerning medical data archiving vary from country 
to country in the European Union but the actual trend is towards long term archiving of 
medical data (about 20 years for any data, up to 70 years for some specific data) and to 
make the patient the owner of its data. 
To ease data storage and communications, the DICOM standard (Digital Image and 
Communication in Medicine) has been supported by several international bodies and 
industrial companies. Most recent image acquisition and treatment devices implement the 
DICOM standard and that eases data exchanges between imagers, post-processing consoles, 
and archiving systems. However, it does not include all features of RIS for data 
management and access, nor does it describe archiving strategies dedicated to PACS. 
Medical data storage strategies can only be established when considering the access 
pattern that depends on the use of these data. The legal trend is for patients to have full read 
access to their medical records. The physicians obviously need access to the data of their 
own patients, however, any physician should not have access to all medical data owned by 
any patient. Other communities may in addition have restricted patient data access needs. 
For instance, researchers may need access to the core data although personal identification 
may not be needed in every case. 
Grids provide a support for the distributed and mass storage of data. Several grid 
middlewares propose distributed and transparent file systems aggregating many storage 
resources to offer extensive storage capacity. Several aspects of grids that are still under 
investigation concern the implementation of data access control and security of data. While 
remaining internal to the hospitals, data security problems are rather easy to solve however 
enabling data exchanges between hospitals over wide area networks makes this matter much 
more complex. Medical data should always be considered as sensitive in general and 
identifying data should remain strictly confidential. In particular this means that data should 
only be accessible by authorised users (for sensitive data) or accredited users (for 
identifying data), often excluding service providers and system managers. Encryption (and 
thus anonymisation) of data on disk and during network transmission is therefore 
mandatory; the access to decryption keys being strictly controlled. 
3.2. BUILDING VIRTUAL DATASETS ON GRIDS 
To enable analysis of medical images related personal and clinical information (e.g. age, 
gender, disease status) has to be identified. The number of parameters that affect the 
appearance of an image is so large that the database of images developed at any single site - 
no matter how large - is unlikely to contain a set of statistically sufficient exemplars in 
response to a query related to one of these domains: 
• Screening programs: to study the distribution of some diseases at a pan-European 
scale and to correlate this information with common factors. 
• Studies on rare diseases for which limited data is available on any single site. 
• Assembling individualised datasets: when studying data from one patient or one 
particular population, one may need to assemble a comparative epidemiological 
dataset by selecting data with similar features at a pan-European scale (same 
gender, age, social category, etc). 
• Alarm networks: to detect the spread of some pathologies over national boundaries. 
Overcoming the problem of data distribution implies constructing a huge, multi-centre - 
federated - database, while overcoming statistical biases such as lifestyle and diet leads to a 
database that may transcend national boundaries. A distributed medical database could be 
used to assemble virtual datasets: i.e. datasets assembled on demand from various data 
sources belonging to different regions and countries for a specific purpose. For any medical 
condition, there would be huge gains in using virtual datasets so long as that (federated) 
database appears to the user as if it were installed in a single site (i.e. a single logical 
dataset). Such a geographically distributed (pan-European) database can be implemented 
using grid technology, and the construction of a prototype would enable a study of the 
suitability of grid technologies for distributed image analyses. 
The medical image analysis community require transparent access to collections of 
image data that may reside in a number of locations inside and outside their hospitals and in 
a number of different formats. It is crucial in deploying any software solution to this 
community that the complexities of those technologies that support virtual datasets are 
hidden from the users and that the essentials of their requirements are satisfied firstly ‘in the 
large’. Only then will the systems analysts and designers responsible for deploying the 
enabling technologies gain the commitment from that user community to develop the 
required infrastructure to satisfy the requirements ‘in the small’. The solution offered for 
virtual datasets must be sensitive to the over-riding issues of data protection and ownership 
(by individuals, by medic and hospitals), data security, medical anonymity and ease of 
access to the data. 
Heterogeneity of image data is one headache in constructing grid-based virtual 
databases of images. It will be necessary for any usable grids medical image 
implementation to integrate multiple datasets be they database-resident or file-resident. To 
this end the requirement for discovery of and interaction with heterogeneous data schema 
needs to be resolved, potentially through the use of high-level meta-data abstractions 
(possibly using ontologies) of each different  dataset. Careful consideration must be given to 
semantic heterogeneity too : different data systems may well refer to the same data item 
with different names or different items with the same name. Identification of patients on a 
large scale is a critical problem too: usually, each hospital internally uses its own individual 
identification mechanism. The need for ensuring the patient’s privacy makes it even more 
difficult. 
The issue of handling annotation is one particular problem in building virtual datasets. 
Annotation can be added to image data in several forms: in radiologists drawing regions of 
interest on medical images (e.g. to denote areas for further study, computer assisted 
detection (CADe), biopsy etc), in radiologists writing medical notes alongside images, in 
technicians supplying written ‘conditions’ under which the image was recorded, and in 
annotation on sets of images, on a particular study or on actual patient records. Any virtual 
dataset would need to cater for these different levels of annotation and allow queries to be 
executed against the semi-structured and/or structured annotation. Clearly there is a need for 
standardisation in image annotation in the medical community (if possible) to enable query 
resolution. 
Any successful medical data system must also provide links between image data and 
non-image data such as biopsies, medical treatment records and patient meta-data. 
Furthermore links between different forms of image (PET, CT, X-ray, mammograms) also 
need to be resolved as do the more general data issues such as privacy, security and 
appropriate role-based access. 
3.2.1. Database indexing 
One of the most important aspects in building large-scale virtual image datasets is the 
ability to perform queries in a transparent and efficient manner. The most standard way to 
formulate these queries is to express conditions on attributes associated to images. 
Nevertheless, these approaches are very intensive both in terms of computational power and 
data manipulations. An intermediate level between direct image access and requests using 
only metadata consists in querying image features. This kind of queries relies on the 
computation of indexes describing either global properties of images or local properties of 
individual image regions, salient objects or topological relations between these objects. 
These indexes can largely contribute to the acceleration of Content-Based Image Retrieval 
(CBIR) since standard database operators can be used, and the direct access to raw image 
data can (most of the time) be avoided.  
However, the indexing of medical images has not retained the attention of researchers 
as much as the indexing of photographic images thus far and the selection of pertinent 
indexing methods, adapted to different kinds of images is a difficult and a very application-
dependant task. There is therefore a real need for standardising the representation of these 
indexes, but also the description of algorithms used for their computation. Some of the key 
issues that have to be solved in a widely distributed image database environment are:  
• The deployment on different geographical sites of indexing algorithms / libraries, 
and the management of new algorithms (or of algorithm version evolution). 
• The indexing policy: which algorithms have to be applied, and which parameters 
are adapted for the different images? When is it necessary to (re)launch the 
indexing? What happens when new images/algorithms are integrated to the 
distributed environment? 
• The “traceability” of indexes: it is crucial for having a pertinent query scheme to 
be able to know which algorithm, in which version, and with which parameters, 
was used to compute a set of indexes. 
• In the case of complex processing, several stages can be chained: the data 
produced by a given algorithm can be used as input of another stage of processing. 
The distributed system must include standardised ways to describe these 
dependencies and must be able to launch the necessary computations in the case of 
insertion of new data, or when a new algorithm is made available. 
The possibility of handling the security of these indexes at different levels may be 
needed: in the same way that personal (nominative) data have to be anonymized for certain 
categories of users, the image data can itself require security, particularly when it permits 
patient identification (e.g. the 3D scanner of a face). However, indexes computed from these 
image data can be considered as public when they do not leave the possibility of patient 
identification. 
3.3. MEDICAL IMAGE PROCESSING 
3.3.1. Image analysis algorithms 
Computerised medical image analysis algorithms have been developed for two decades 
or so. The aim is to assist the clinicians in facing the amount of data by providing reliable 
and reproducible assistance to diagnosis and therapy. Indeed, the manual processing of 3D 
images is very fastidious and often error prone. Moreover, 3D medical image interpretation 
requires a mental reconstruction for physicians and is subject to large inter-operator 
variations. 
Although image processing algorithms can provide accurate quantitative measurements 
(e.g. the measurement of the heart left ventricle ejection fraction from dynamic image 
sequences) or can accomplish some tasks that are not feasible by hand (e.g. accurate 
registration of multi-modal images), the reliability and the responsibility issues remain key 
showstoppers to their large scale development. Algorithm validation is often made difficult 
due to the lack of provable theory in order to compare with processing results and their 
development tends to be limited in scale. 
Some medical image analysis algorithms are also very computing intensive (e.g. 
stochastic algorithms like Markovian models, Monte Carlo simulations). Therefore, some 
algorithms that are known to produce better results are not used in practice due to a lack of 
computing power. Given that a sufficient amount of computing resources is available, 
parallelization is often a means to significantly speed-up these algorithms. 
 
Grid technologies will not only provide access to large amount of data for testing. It 
will also enable image processing communities to share common datasets for algorithm 
comparison and validation. They will offer an access to large processing power suited to 
processing full datasets in reasonable time, compatible with the needs for experiencing new 
algorithms. They will also ease the sharing of algorithms developed by different research 
groups thus encouraging comparative studies. For all these reasons, grid technologies are 
expected to boost the production of medical image analysis algorithms and to facilitate their 
quality improvement. 
3.3.2. Registration 
Registration techniques have encountered considerable success in the medical image 
processing community not only as they permit the production of average models but also 
because they ease the comparison of image data coming from multiple sources. Registration 
may be intra-patient (when registering data coming from a same patient but acquired at 
different time and/or on different imagers) or inter-patient (when comparing data from 
different patients). It can be mono-modal (when registering images acquired using the same 
image modality) or multi-modal. The matching criteria used to perform optimisation 
depends on the kind of registration performed. But there is another categorisation of 
registration algorithm that has a largest impact on the optimisation procedure and its 
computational cost: one often differentiates between rigid and non-rigid registration 
algorithms. 
Rigid registration algorithms concern the registration of intra-patient data: data images 
are considered to represent the same physical body (although it might appear quite 
differently in different acquisition modalities) and the registration procedure search for a 
rigid transformation (a composition of a translation and a rotation) to match the two images. 
Rigid transformations are described by 6 parameters only (3 degrees of freedom in 
translation and 3 degrees of freedom in rotation) and the associated optimisation process is 
usually reasonably tractable, unless processing very large dataset. Common extensions to 
rigid registration include similarity registration (7 degrees of freedom, adding a scale factor) 
or affine registration (12 degrees of freedom, adding anisotropic scale factors and shear 
factors). 
Non-rigid registration algorithms concern the alignment of data acquired from different 
patients and representing similar but different shapes. Non-rigid registration is more 
complex than rigid registration as the transformation includes many more degrees of 
freedom (it is often a parametric transformation with variable degree of complexity or a 
dense transformation field). Therefore, non-rigid registration algorithms are much more 
costly (up to hours of computation time on today’s workstations) and parallelization of 
some algorithms has been proposed. One of the key challenges to share non-rigid 
registration algorithms on a grid is the standardisation of the transformation format. 
Currently, transformation models as different as B-splines, NURBS, radial basis functions, 
or dense displacement fields are used to encode the deformation. A common framework 
will be needed to handle, compare and use all these models. 
Image intensity correction techniques also often rely on optimisation procedures and 
therefore may fall in the compute intensive algorithms described in the previous section. 
3.3.3. Interactive image processing algorithms 
Another particularity of medical image processing algorithms is that some of them need 
to be executed interactively. There are two main reasons why a medical application might 
need to be interactive: 
• To solve reliability problems: to ensure that the user gets full control of the 
algorithm output by interactive guidance. 
• To solve legal responsibility issues: automatic processing of medical data often 
raises the problem of legal responsibility. A user-guided algorithm is not subject to 
this kind of criticism. 
To ensure interactivity, an algorithm needs to be executed in a time short enough for 
the user to remain active in front of the screen (usually the whole process should not exceed 
a few minutes in the medical context). Grid infrastructures can provide the computing 
power needed to ensure that the execution time remains reasonable by allocating powerful 
computing resources for interactive jobs or by empowering parallel applications. However, 
porting interactive applications on a grid is made complex by the need to split the user 
interface (that displays the algorithm progress result on the user's screen) and the computing 
algorithm (that is remotely executed on the grid resources). Therefore, interactive 
applications have to be carefully designed in order to be ported onto grids. 
A typical user-guided interactive medical application is that of segmentation algorithms. 
Medical image segmentation is a complex problem for which there exists no general 
solution. Most segmentation algorithms such as deformable models or voxel clustering 
algorithms are iterative. It is therefore possible to update the algorithm progress on the user 
screen periodically and to take into account some user input at each stage to guide the 
algorithm while it is progressing. Likewise, enabling interaction with grid-powered non-
rigid registration algorithms would enable correction of mistakes created by local minima 
(especially in multi-subject brain registration) while retaining the accuracy of the automatic 
processing and a reasonable human computation time. 
 
Mammograms analysis for breast cancer screening 
One current example of a large-scale medical image acquisition and processing application is the 
automated detection of malignant tumours in mammograms developed to support breast cancer 
screening programs that are starting in several European countries today. Screening programs at a 
national scale require the reading of a huge number of images (e.g. one mammogram for each woman 
older than 40 years every 2 years) thus considerably increasing the burden of image analysis on 
radiologists. Grid-enabled mammogram analysis projects aim to prove the viability of the grid by 
harnessing its power to enable radiologists from geographically dispersed hospitals to share 
standardised mammograms, to compare diagnoses (with and without computer aided detection of 
tumours) and to perform sophisticated epidemiological studies across national boundaries. Research is 
currently being conducted into imaging workstation architectures, into information infrastructures to 
connect radiologists across a grid, and into DICOM-compliant object models residing in multiple, 
distributed data stores, as well as into mammogram indexing, etc. There are a number of relevant 
technologies that are being harnessed together to provide a distributed infrastructure to support 
radiologists in their work. These include mammogram analysis algorithms, grid middleware 
implementations, and computer-aided detection software. 
However they have only just scraped the surface in matching these user requirements. Data 
heterogeneity is one major issue in the storage and analysis of medical images – even in a single 
region of a single country never mind inter-regional or international data differences. The ability to 
process unstructured (e.g. radiologists annotations), semi-structured (patients’ medical history) as well 
as rigidly structured patient data (metadata such as age, drug treatments, etc) is essential to enable the 
controlled execution of epidemiological studies or other query-based analyses. 
 
 
 
 
 
4. Computational Models of the Human Body 
4.1. THERAPY PLANNING AND COMPUTER ASSISTED INTERVENTION 
Beyond medical data acquisition and analysis, modelling of the human body 
enables specific medical treatments. The key distinguishing factor compared with image 
processing or image reconstruction in the same application domain is the use of 
computational methods for predictive purposes – providing physically accurate (within 
modelling accuracy) information that is not included in medical images themselves.  
Enormous progress has been made in recent years (aided by the increases in 
performance of computing platforms) and numerical modelling is now able to provide 
realistic (and validated) predictions of very complex phenomena. However, there is a real 
need for the continued development of numerical modelling and simulation technology to 
address the future challenges of multi-scale, multi-physics problems that arise naturally and 
automatically in virtual human modelling.  
Given the complexity and the computing cost of most human body models, grid 
technologies are a good candidate to face computation challenges arising in this area. 
4.2. ATLASES 
Atlases have long been used in medicine for anatomy and physiology studies. For 
centuries, atlases have been produced manually by experts from their knowledge of the 
human body. Atlases attempt to provide a 'standard' description of the human body or parts 
of it. They are very dependent on the designer and have been incrementally refined with the 
progress of medicine. They tend to be general and hardly take into account infrequent 
parameters. 
With the advent of digital images and image registration algorithms, the production of 
digital atlases has become possible. Digital atlases are assembled by registering large 
training sets in a common frame and averaging the registered images by different means. 
Digital atlases prove to be much easier to produce than manual atlases. They have 
encountered a tremendous success and have lead to significant research progresses, 
especially in the domain of brain imaging. The production of atlases require the availability 
of training  datasets large enough to be statistically representative of the population under 
study and of sufficient computation power for accomplishing the registration and intensity 
correction computations. Grid technologies promise to cover both aspects and should 
therefore boost the production of anatomical and functional atlases of the human body. 
Given a wide scale medical information system and considerable computing power, one can 
even imagine producing on-the-fly individualized atlases. For example a physician may 
want to study the brain of a 50 year-old male subject to multiple sclerosis; he could ask for 
the production of an atlas from a training set with matching criteria. Such an individualised 
atlas would prove to be much more specific and precise than a generic atlas. 
4.3. NUMERICAL SIMULATIONS OF THE HUMAN BODY 
The release, some years ago, of the Visible Human (VH) dataset made it possible, 
for the first time, to access anatomical information without compromises. This produced a 
significant momentum in many areas.  However, after some time it became clear that, while 
the dissection approach used in the VH project ensured extreme quality, it also lacked 
physiological information that other forms of data contain. These include in vivo data 
collection, multi-subject, gender, sex, and age variations, lack of connection with functional 
information, no pathology, etc. Many research projects have been carried out in Europe over 
the last few years to try to circumvent some of these limitations. A basic feature of the VH 
project, lacking in all these other projects, is completeness. The VH project relates ONLY 
to the normal anatomy of one human subject, and provides ALL the anatomical information 
for that subject. The other projects focused only on specific aspects. Because of the lack of 
the necessary critical mass, none has dared to search for completeness. 
The Living Human Project (LHP) intends to develop a world-wide, distributed 
repository of anatomo-functional data and of simulation algorithms, fully integrated into a 
seamless simulation environment and directly accessible by any researcher in the world. 
The objective is patient-specific bionumerics and image processing (both for pre-processing 
and visualisation) for the complete human body. It requires the integration of individual 
systems through hierarchical approaches at the algorithmic level. With the development of 
grid and large medical databases, one can expect the development of more specific or even 
individualised models. These models could be built from specific patient data and target 
specific pathologies or functions. 
Many areas of development in numerical human modelling are already at the stage 
that they can be used by medical researchers as tools for investigation into cause of medical 
problems and treatment procedures. Research into cardio-vascular disease in particular is an 
area where HPC simulation software is widely used, for example to improve understanding 
of processes leading to illness or to failure of implants such as artificial heart-valves or 
stents.  
The interest of the grid approach is to provide services to medical or clinical users, 
removing any need for them to have to handle the details of any computing systems or 
simulation methods. Grid technologies are also required to provide high-bandwidth to large 
collections of coarse-grained, distributed, non-textual, multidimensional, time-varying 
resources. Web services technologies are required to cope with the dynamic aspects of a 
digital library that provides not only data, but also simulation services, collaborative work 
services, interactive visualisation services, and so on. 
Broadening the term “medical supplier” to include pharmaceutical industries, the 
acceptance of the potential benefits of using numerical simulation tools (i.e. actual use or 
willingness to investigate use) is already well established within the R&D divisions of 
companies. For large companies, grid offers the means to deploy simulation software across 
their own distributed resources.  There are also established SME’s supplying services and 
consultancy based on numerical simulation. Future grid developments will allow them to 
enter into virtual organisations with their customers (including controlled access to data 
sources) and to have access to external computational resources when needed. 
4.4. ISSUES FOR THERAPY PLANNING 
Many human body models have been developed for therapy planning. Examples of 
numerical simulation used by health practitioners include radio-surgery/radio-therapy 
planning (see section 4.3.2), electromagnetic source localisation (an inverse procedure to 
identify areas of disorder within the brain based on external EEG/MEG measurements), 
reconstructive maxillofacial surgery (see section 4.3.1), etc. Today, most developments are 
in the transition between research use and clinical use.  Grid can be used to provide access 
to appropriate computational services and deliver these to medical users. Healthgrid would 
need large scale deployment studies to allow the evaluation of a wide range of requirements, 
including local deployment aspects and practical experience with production grid use. The 
major challenges will be to ensure that services can be delivered into the user’s workplace 
in an appropriate, ergonomic manner and that security, policy and legal constraints related 
to the use of patient data are fulfilled. 
 
A grid scenario for radiotherapy planning and treatment  
From a technology point of view, radiotherapy is a highly complex procedure, involving a 
variety of computational operations for data gathering, processing and control. The modularity of the 
treatment process and the need of large data sets from different sources and nature (physics, 
mathematics, bio-statistics, biology, and medicine) make it a privileged candidate for healthgrid 
applications. 
In an enlarged Europe sharing data, expertise and computational resources will be a 
significant factor for a successful cost containment and improved access to a high overall quality of 
care in radiotherapy. It is an ideal tool for harmonising the cancer treatment as well as providing a 
common base for research collaboration.  
Presently patients are treated with standardised radiation doses.  Gene profiling may enable 
an individualised adjustment of the dose so as to achieve tumour control in patients with a low 
radiosensitivity and avoid severe side effects in patients with above average sensitivity to radiation. In 
a first step a grid structure should allow research groups, each focusing on different molecular 
mechanisms, to access data in the distributed infrastructure for comparison studies.  In a next step 
users should be able to submit the results of predictive tests for analysis to a shared software and 
expert platform for radiosensitivity grading. 
A similar approach can be followed for other aspects clinical decision making such as the 
assessment a tumour’s capacity for metastatic spread.  For rapidly metastasising tumours, systemic 
(chemotherapy) treatment needs to be associated to the locally delivered radiotherapy. New tests now 
under development, predicting on the basis of gene profiling which tumours are most likely to 
metastasise, can make 60% of the chemotherapy currently administered e.g. for breast cancer, 
redundant. However, it takes a highly specialised team to interpret the results of these tests correctly. 
Grid-supported consultation of libraries of gene profiles or, alternatively, tele-consulting services offer 
also in these case excellent perspectives. 
 Tissue electron density provided by CT scanning is still needed to calculate the dose 
delivered by photon and electron beams. To define the planning target volume (PTV) and organs-at-
risk (OAR), new imaging modalities based on MR-imaging, MR-spectroscopy and PET are far 
superior and become a requirement for high-precision high-dose radiotherapy. In contrast to CT 
scanning, the latter imaging modalities are available only in reference centres for reasons of cost and 
expertise. To secure access for all patients to optimal imaging for radiotherapy planning, the 
coordinating centre could perform a grid-mediated selection of an imaging centre, and the resulting 
complementary image acquisitions could be sent back through the grid. To reproduce the patient 
positioning and perform the complementary imaging in treatment-relevant conditions, the patient-
individual immobilisation devices could be physically sent to the imaging centre. Alternatively, a 
retrospective registration grid service could be used to realign all the images in the relevant coordinate 
system.  
Many tools have been developed for computer-aided definition of PTV and OAR including 
anatomical atlases that can be warped to the patient-individual anatomy. A grid could make such tools 
and their upgrades in due time available to all groups involved in PTV and OAR definition. Nodes on 
the grid that provide expert help for patient-related problems in defining PTV and OAR are needed. 
Accuracy of Monte Carlo (MC) dose computation is excellent, provided that the computing 
power is sufficient to allow for enough runs to reduce the statistical noise. The grid is a natural 
alternative to costly parallel computers. In this way, MC dose computations could become standard 
for radiotherapy quality assurance (QA), planning, and plan optimisation years before individual 
departments could afford a local investment that is capable to support MC. Requirements needed for 
such deployment include the existence of a service level agreement between the departments and the 
grid providers by which the grid level of performances in terms of security, stability and response time 
is guaranteed. 
Each delivery centre manages the commissioning of its own treatment units and incorporates 
both mechanical-physical and dosimetric parameters, including uncertainty flags, into an identity card 
that is accessible through the grid. This identity card will allow treatment-planning providers and 
computation services to establish, refine or fit their computational model of the linear accelerator. The 
identity card also contains the reference data so that periodical quality assurance (QA) procedures 
could make sure that the machine performs accordingly. One might expect that the cooperation 
through the grid between QA providers and delivery centres will streamline the QA procedures and 
harmonise the identity cards over the different accelerator types.  
The quality assurance of the treatment can also benefit from the grid, even if it is patient 
specific: once a treatment plan has been designed, some locations are selected to measure the dose 
level in a physical phantom that replaces the patient during the first treatment session. In parallel, the 
coordinating centre consults the grid for an independent dose computation service to compute the dose 
in the same set of points in the phantom. The comparison of the measured dose to the computed 
fractional dose is performed automatically at the delivery centre and will be submitted to the 
coordinating centre.  In case of violation of tolerances, the treatment plan will be recomputed in 
patient and phantom by a second dose computation service in the grid. Alternatively, the coordinating 
centre may consult the grid for a virtual treatment at another delivery centre. 
 
 
4.5. TOWARD REAL-TIME CONSTRAINTS 
Some medical applications such as surgery simulation are more demanding and require real-
time computations. Real-time is a challenging problem for grid infrastructures today. 
Although grids can provide additional computing power, distributing computations to 
remote resources if often done at the price of an initialisation cost that can be significant 
(from minutes to hours in common batch-oriented scheduling systems). To empower real-
time applications, a grid middleware would need to ensure immediate execution of real-time 
code. Strong network requirements are also dictated by real-time constraints. Grid services 
dealing with jobs as sensitive as surgery simulation and computer assisted intervention 
should also have the capacity to make advance reservation of resources and to cope with 
any emergency situations: the requested computation and networking resources must be 
allocated when the surgery starts and it should be possible to submit prioritised jobs in case 
of emergency with resource requisition and contention resolution as required. 
4.5.1. Surgery simulation 
Surgery simulation is the aim of many research activities today: it is a promising 
tool both in planning surgery and in training surgeons. Realistic surgery simulation usually 
involves complex biophysical models of the human body. The building of a model for 
surgery simulation (e.g. using finite element modelling) and its use in an interactive context 
have to be distinguished: building the model may require intensive and long term effort, but 
its final formulation should enable very fast computation for the purpose of the simulation 
itself (deformation of organs, evolution of physiology, etc). 
Given the complexity of human body modelling, surgery simulators are often 
limited to a specific intervention procedure. Another constraint is the mechanical devices 
manipulated by the practitioner during the intervention: an endovascular intervention 
procedure or a laparoscopic surgery intervention are more easily simulated than open 
surgery since they require visual and haptic feedback devices with limited capabilities. 
Development of open surgery simulation tools is also limited today by the state-of-the-art in 
3D rendering and full degree of freedom devices. Even considering only limited 
intervention procedures, the computations involved may be very difficult to achieve in real 
time: visual feedback is known to require an update frequency of 25 Hz and realistic haptic 
feedback may require much higher frequencies (up to 300 Hz for soft tissues and thousands 
of Hz for rigid material such as bone).  While a great deal of progress in grid technologies, 
both in power and bandwidth, may be anticipated, there are further demands to be place on 
it.  For example, the compositional integration of various models (mechanics, visual 
rendering, device interactions, etc) would be yet another requirement, if grid is to enable 
more realistic and broader real-time simulation tools.  
4.5.2. Augmented reality and computer assisted intervention 
The next stage in real-time modelling of biophysics is its coupling with 
intervention data in order to bring additional information that could not be observed during 
a medical intervention. For instance, augmented reality consists in superimposing on the 
scene that the practitioner perceives additional information coming from a computerised 
model, usually through visual devices. This enhanced perception proves to be useful in 
many types of interventions: it allows a neurosurgeon to visualise the brain tumour he has to 
remove by projecting it on the head of the patient prior to and during the intervention, e.g. 
to guide its resection; or it aids a dentist to visualise the planned position and axis of drilling 
to place an implant; or a radiologist to guide the placement of a needle for a biopsy or a 
radio frequency ablation. In all these cases, augmented reality helps reduce the invasiveness 
of the procedure. 
Many currently existing augmented reality systems rely on simplified models 
where only a simple calibration step is required, simply because this is computationally 
tractable. Indeed, more complex augmented reality applications need huge computing 
power for the pre-operative construction of patient-specific models and for the per-operative 
adaptation of these models to reality (registration, geometric deformations, etc). Going to 
the complete integration of a bio-physical model into a clinical augmented reality system is 
a challenging task where the grid could be the key. However, this would imply very strong 
requirements on the security and dedication of the computer and network resources in order 
to ensure the reliability of the real-time system. 
Another way to enhance practitioner capabilities is to provide a computer assisted 
action, for instance though the use of robots. Even if the robot is passive (e.g. a robot-arm 
guided by a surgeon), it brings a large benefit such as minimizing human arm motion and 
filtering out any hand tremor. Active robots may provide even more benefit, for instance by 
compensating for organ motion to give the surgeon the illusion of working on a static 
structure. By decoupling perception (using augmented reality) from action (using robots), it 
has been possible to separate the surgeon from the patient, and remote surgery has proved to 
be possible through the use of high bandwidth dedicated networks.  Manipulating the 
controls through networks from a distant location certainly raises the problem of network 
performance and quality of service: the data flow is critical and a guaranteed bandwidth 
mandatory.  
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5. Grid-Enabled Pharmaceutical R&D: Pharmagrids 
The Pharmaceutical R&D enterprise presents unique challenges for Information 
Technologists and Computer Scientists. The diversity and complexity of the information 
required to arrive at well-founded decisions based on both scientific and business criteria is 
remarkable and well-recognized in the industry. The decisions can form the basis for multi-
year multi-person multi-millions of Euro investments and can create new scientific territory 
and intellectual property. Thus all aspects of managing, sharing and understanding this 
information is critical to the R&D process and subject to substantial investment and 
exploration of new informatics approaches. 
Pharmaceutical R&D information includes are large variety of scientific data as well as 
sources of critical organizational information such as project and financial management data 
and competitor intelligence information. This data takes some fairly unique formats as well. 
Examples are images, models, sequences, full text scientific reports, records of prescriptions 
and physician encounter re-imbursements. These sources of information consist of internal 
proprietary, external commercial and open-source data. 
The problems range from knowledge-representation and integration, to distributed 
systems search and access control, to data mining and knowledge management, to real-time 
modelling and simulations, to algorithm development and computational complexity. 
Grid technology holds out the promise of more effective means to manage information 
and enhance knowledge-based processes in just the sort of environment that is well 
established in pharmaceutical R&D. 
A pharmaceutical Grid should be a shared in silico resource to guarantee and preserve 
knowledge in the areas of discovery, development, manufacturing, marketing and sales of 
new drug therapies [5.3] and cover three dimensions: 
• a resource that provides extremely large CPU power to perform computing intense 
tasks in a transparent way by means of an automated job submission and 
distribution facility 
• a resource that provides transparent and secure access to storage and archiving of 
large amounts of data in an automated and self-organized mode 
• a resource that connects, analyses and structures data and information in a 
transparent mode according to pre-defined rules (science or business process 
based) 
Pharmaceutical grids open the perspective of cheaper and faster drug development. 
Pharmaceutical grids should enable parallel processes in drug development, away from the 
traditional approach where target discovery, target validation, lead discovery, lead 
optimization and transition to development take on average 12 years. These parallel 
processes would take advantage of in silico science platforms for target identification and 
validation, compounds screening and optimization, clinical trials simulation for detection of 
deficiencies in drug absorption, distribution, metabolism and elimination. 
 
Pharmaceutical grid for a rare disease 
Infectious diseases kill 14 million people each year, more than ninety percent of whom are in the 
developing world. Access to treatment for these diseases is problematic because the medicines are 
unaffordable, some have become ineffective due to resistance, and others are not appropriately 
adapted to specific local conditions and constraints. Despite the enormous burden of disease, drug 
discovery and development targeted at infectious and parasitic diseases in poor countries has virtually 
ground to a standstill, so that these diseases are de facto neglected.  At the same time, the efficacy of 
existing treatments has fallen, due mainly to emerging drug resistance. 
Rare Diseases represent grave personal tragedies and in toto substantial health and economic 
burdens even for the wealthiest nations [5.4]. Nor is it always true that there is no economic driving 
force for the development of therapeutic interventions for rare diseases [5.5]. 
The unavailability of appropriate drugs to treat neglected diseases is among other factors a result of 
the lack of ongoing or well coordinated R&D into these diseases. While basic research often takes 
place in university or government labs, development is almost exclusively done by the pharmaceutical 
and biotech industry, and the most significant gap is in the translation of basic research through to 
drug development from the public to the private sector. Another critical point is the launching of 
clinical trials for promising candidate drugs.  
Producing more drugs for neglected diseases requires building a focussed, disease-specific R&D 
agenda including short-, mid- and long-term projects. It requires also a public-private partnership 
through efficient, secure and trusted collaborations that aim to improve access to drugs and stimulate 
discovery of easy-to-use, affordable, effective drugs. The goal is to lower the barrier to such 
substantive interactions in order to increase the return on investment for the development of new 
drugs.  
A ‘pharmagrid’ should create a virtual organization and collaborative environment which will 
motivate and gather together: 
• drug designers to identify new targets and drugs 
• healthcare centres involved in clinical tests 
• healthcare centres collecting patent information 
• organizations involved in distributing existing treatments  
• informatics technology developers  
• computing and computer science centres 
• biomedical laboratories working on vaccines, genomes of the virus and/or the parasite and/or the 
parasite vector 
Pharmagrid will support such processes as:  
• search of new drug targets through post-genomics requiring data management and computing 
• massive docking to search for new drugs requiring high performance computing and data storage 
• handling of clinical tests and patient data  requiring data storage and management 
• overseeing the distribution of the existing drugs requiring data storage and management 
• trusted exchange of IP, possibly auction-mediated 
A grid dedicated to research and development on a given disease should provide:  
• resources for computationally intensive search for new targets and virtual docking 
• resources for massive storage of post genomics and virtual docking data output 
• grid portal access to  post genomics and virtual docking data 
• grid portal to access medical information (clinical tests, drug distribution, etc.) 
• a collaboration environment for the participating partners.  
For competitive and intellectual property protection reasons, pharmaceutical Grids will 
predominantly be private enterprise-wide internal grids with strict control and standards.   
At least this will likely be the case in the near-term as more and more R&D organizations 
explore and become comfortable with this technology and its potential. 
However, the promise of the grid to create effective virtual organizations based on 
efficient secure and trusted-collaborations will create the foundation for new forms of 
partnerships – amongst commercial, academic, government and international R&D 
organizations. 
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Figure: Concrete Structure of a Grid for Rare Diseases. 
 
 
The Basic Grid Technology layer comprises the basic grid engine for scheduling and brokering of 
resources. The Virtual Organization (VO) layer integrates users from different and heterogeneous 
organizations. Access rights, security (encryption), trust buildings are issues to be addressed and 
solved on this layer. The Distributed Data Access / Information Retrieval layer addresses one of the 
major challenges: the problem of semantic inconsistency between biological and chemical databases is 
even more urgent in the grid context. Ontology-based mediation services for data integration might 
provide one road to go for a grid for rare diseases; another option would be to make use of 
developments from other grid projects (e.g. the distributed query processor (DQP) [5.6] or the 
federated version of SRS [5.7]) The Integration of Application layer will require substantial meta-
information on algorithms and input / output formats if tools are to be interoperable in the grid. 
Assembly of tools for virtual screening into complex workflows will only be possible if data formats 
are compatible and semantic relationships between objects shared or transferred in workflows are 
clear. Next comes the Workflow layer. One core element of a grid for rare diseases is the virtual 
screening machine including, amongst other functionalities, a generator for focused virtual libraries, 
high throughput docking software, different filters for pre- and post-processing of hits in the virtual 
screening procedure and software for the prediction of basic ADME parameters. The combination of 
the tools behind these functionalities in a workflow and the execution of this workflow in the grid 
requires a formal description as provided e.g. by WPDL [5.8] or SWFL [5.9, 5.10]. The Ontology / 
Knowledge Representation layer maintains formalized knowledge representations (ontologies).  These 
must play a key role in any future pharmaceutical grid. A grid for rare diseases would require 
significant activity to construct an ontology for the disease under investigation, for genetic 
epidemiology aspects including the categorization of clinical phenotypes. Moreover, a pharmaceutical 
ontology would have to bridge from biology to chemistry as it would have to describe formally a 
pharmaceutical target as well as the concept of an “in silico screening hit” and its development into a 
“lead compound” for experimental evaluation. The Data and Knowledge Mining Services layer 
includes services for statistical approaches to data mining (e.g. in the field of epidemiology) and 
learning and optimization of in silico drug discovery approaches. Knowledge mining services will 
largely depend on the availability of a pharmaceutical ontology. Interoperability of statistical models 
as well as the issue of comparability of predictions made on the basis of these statistical models. 
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6. Grids for epidemiological studies 
Conventional epidemiology requires extensive collections of data concerning 
populations, health and disease patterns, as well as environmental factors such as diet, 
climate and social conditions.  A study may focus on a particular region or a particular 
outbreak, or it may take as its theme the epidemiology of a condition across a wide area.  
The range of data required will, therefore, vary with the type of study, but certain elements 
persist: a degree of trust in the data is essential, so its ‘provenance’ has to be assured and the 
standards of clinical practice under which it was obtained have to be above a certain 
threshold.  Where the data has been gathered under different clinical regimes, it must be 
possible to establish their semantic equivalence, to ensure that aggregation or comparison of 
datasets is legitimate.  Ethical issues may also arise if data collected in the first place in the 
course of individual health care is to be used for research. 
The analysis of aggregated data requires the construction of complex models and the 
use of sophisticated statistical tools.  This has necessitated collaboration between physicians 
and statisticians, and the rise of epidemiology as a discipline.  The impact of genomic 
analysis will extend the kinds of variable under study and the range of expertise to be 
applied. 
The technology to allow federation of databases stored locally in hospitals has existed 
for some time.  It is possible for these databases to be queried for epidemiological purposes 
while preserving patient anonymity. Such distributed queries may be managed and 
supervised by the hospitals with primary responsibility for the data, ensuring compliance 
with ethical and legal regulatory frameworks.  None the less, the political difficulties 
inherent in the integration of information systems are well known and this has plainly not 
happened to the degree that it is possible despite major government efforts. 
Grids supervene mere integration of databases. They can enforce the interoperability of 
tools and analysis services and they may also enforce common standards and semantic 
clarity about database content and tool input / output.  Indeed, the Grid-based federation of 
retrieval systems provides a significant alternative to federation of databases. We may not 
see the latter for quite some time: federation of databases requires – in case the databases 
should be interoperable – clear semantics and standards based on conventions about 
semantics.  Attempts to use semantics-based mediators have not been particularly successful 
so far. 
In contrast to bioinformatics, where at least two major systems for data integration are 
in use (ENTREZ at the NCBI and SRS at EBI), no such integration layer exists in the field 
of medical informatics. 
One road to go for the integration of medical data would be to adopt Grid strategies for 
data integration developed for bioinformatics. In SIMDAT, an Integrated Project funded in 
the course of the FP6 IST programme, federation of the data integration system SRS is one 
of the major R&D goals defined for this project.  
If such an approach is adopted, the cost and effort for establishing completely new 
databases in the field of clinical research / genetic epidemiology would be significantly 
limited, thus paving the way for smooth and rapid implementation of first demonstrators. 
The proposed adoption of federated SRS as a data integration platform for medical 
(phenotype) data should not at all prevent a HealthGrid community in the field of genetic 
epidemiology from doing their homework on standards. Any type of interoperability 
requires a broad and common understanding of data types and applications. Therefore, 
domain-specific meta-data will play a crucial role in Grids for genetic epidemiology (as 
much as in all other HealthGrid scenarios) to enable interoperability of analysis methods 
and comparability of data and results. 
6.1. DATA SEMANTICS IN GENETIC EPIDEMIOLOGY 
Standardised semantics will be essential for genetic epidemiology. Although a 
significant portion of developments done in the context of the semantic web will be relevant 
and partially re-useable for biomedical Grids, domains such as genetic epidemiology will 
need dedicated initiatives for clarified semantics carried on by experts in the field. Unified 
naming of phenotypes and standardised acquisition and recording of clinical parameters 
have to be supported by a Grid for genetic epidemiology. One of the central services in a 
Grid for genetic epidemiology studies has to be a clinical annotation service for clinical 
phenotype descriptions. Such an annotation service has to be user – friendly, easy to use by 
non-computer-experts and it has to make use of widely accepted naming concepts in the 
domain of genetic epidemiology (if they exist at all). One possible solution to the problem 
of a Grid-based annotation service for clinical phenotypes would be an ontology-based 
annotation service which would allow navigation through controlled vocabularies and 
selection and linking of defined concepts to entries in existing databases for phenotype 
recording.  
6.2. IMAGE ORIENTED EPIDEMIOLOGY 
The specific requirements for the use of Grid technology related to imaging have been 
discussed in chapter 3. Here we will only address the specific issues related to the use of 
images in epidemiological studies. 
Patient management (diagnosis, treatment, continuing care, post-treatment assessment) 
is rarely straightforward; but there are a number of factors that make patient management 
based on medical images particularly difficult. Often very large quantities of data, with 
complex structure, are involved (such as 3-D images, time sequences, multiple imaging 
protocols).  In most cases, no single imaging modality suffices, since there are many 
parameters that affect the appearance of an image and because clinically and 
epidemiologically significant signs are subtle.  Among the many relevant factors are patient 
age, diet, lifestyle and clinical history, image acquisition parameters, and anatomical and 
physiological variations.  Thus any database of images developed at a single site– no matter 
how large – is unlikely to contain a large enough set of exemplars in response to any given 
query to be statistically significant. Overcoming this problem implies constructing a very 
large, federated database, while controlling for statistical biases such as lifestyle and diet 
almost certainly leads to a database that must transcend national boundaries. Realizing such 
a geographically distributed (pan-European) database necessitates so-called Grid technology 
[4], and the construction of a prototype would push emerging Grid technology to its limits. 
 
 
The MammoGrid project: 
The MammoGrid [5] project is providing a collaborative Grid-based image analysis platform in which 
statistically significant sets of mammograms can be shared between clinicians across Europe. The 
applications to be implemented can be thought of as addressing three main problems: 
• Image variability, due to differences in acquisition processes and to differences in the 
software packages (and underlying algorithms) used in their processing. 
• Population variability, which causes regional differences affecting the various criteria used 
for the screening and treatment of breast cancer. 
• Support for radiologists, in the form of tele-collaboration, second opinion, training, quality 
control of images and a growing evidence-base. 
In practical terms, the project will: 
• evaluate current Grids technologies and determine the requirements for Grid-compliance in 
a pan-European mammography database; 
• implement a prototype MammoGrid database, using novel Grid-compliant and federated-
database technologies that will provide improved access to distributed data;  
• deploy versions of a standardization system (SMF – the Standard MammoGram Form [6]) 
that enables comparison of mammograms in terms of tissue properties independently of 
scanner settings, and to explore its place in the context of medical image formats; and 
• use the annotated information and the images in the database to benchmark the performance 
of the prototype system. 
The European dimension of the MammoGrid consortium, including hospitals in north and south 
Europe, provide the first opportunity for statistical studies of breast cancer to be conducted and 
analyses to be made on geographical, cultural, environmental and temporal influences on cancer 
development. MammoGrid should provide statistically significant numbers of exemplars even for rare 
conditions of cancer development and will therefore enable more diverse epidemiological studies than 
hitherto have been possible. The project will develop standard data formats and strict automated 
quality checks, which will lead to improved and normalised breast screening procedures. Such a 
secure, efficient and standardised storage of medical knowledge in an EU-wide federated database 
will also provide an ideal educational tool for training radiographers and radiologists. Standardisation 
on data formats will control the variation in the quality of images and diagnoses in European 
healthcare. 
 
6.3. BUILDING POPULATION-BASED DATASETS  
A European Grid for Genetic Epidemiology would open completely new perspectives 
for gathering data on large populations and – as a consequence – would allow stratification 
of large cohorts for large scale European Genetic Epidemiology studies.  One possible 
problem that we foresee in this context is that there are regional, legal and cultural 
differences that may obstruct the building of pan-European, population-based datasets. As a 
consequence, we propose to complement any type of HealthGrid activity that could possibly 
encounter problems of this type is supplemented and accompanied by research activities in 
the field of ethical, legal, and cultural aspects that might impact future healthgrids. 
The current situation in Europe is quite heterogeneous. Initiatives to build large 
population-based datasets have been started in Iceland [9], the UK [10], and in one Baltic 
state, Estonia [11]. These national initiatives are driven by a different rational: whereas in 
Iceland it was a private-public partnership between DECODE genetics and the government 
of Iceland in the UK and in Estonia the initiatives are based on governmental scientific 
research programmes. In how far commercial aspects will interfere with the goals of a pan-
European initiative to build population-based datasets remains unclear, however, it is clear 
that large population-based datasets (and associated sample collections) are not only 
interesting for basic science but also for the pharmaceutical industry.  
Even though we foresee problems as discussed above, the chances that come with large 
scale studies and pan-European population-based datasets will exceed the risks of potential 
abuse of genetic information by and large. Currently, genetic epidemiology studies suffer 
from low numbers of samples, inconsistent acquisition of bio-parameters and complex 
genetics. 
6.4. STATISTICAL STUDIES 
Built on population-based datasets statistical studies on the influence of allelic 
predisposition, behavioural aspects, nutrition habits, regional or national healthcare 
management and many other parameters will be possible. A central task for a Grid project 
for genetic epidemiology would be to enable and to promote interoperability of statistical 
analysis tools. Similar to initiatives in the field of systems biology an exchange service for 
statistical models based on a common understanding and classification scheme of statistical 
approaches would be needed. A point to start with would be a “tool box” of statistical 
models including relevant meta-information on algorithms, modelling strategies and 
constrains, application scenarios and possible equivalence or variations of statistical models. 
As a Grid service this tools box would allow easy exchange of methods and improve 
interoperability of statistical models and data mining capabilities on the side of the users of 
the Genetic Epidemiology Grid. 
6.5. PATHOLOGIES EVOLUTION IN LONGITUDINAL STUDIES 
The study of pathologies follow-up would include information related to regular hospital 
visits, home-care monitoring of signs and symptoms, recording of interventions and drug 
effects, environmental issues etc. However, these studies are usually fragmented and non-
uniform, thus, cannot result in common conclusions. One can see this issue from two 
standpoints: a) how pathology follow-up or the setup of clinical trials can be supported, and 
b) how the results of clinical trials can be better utilized in a manner that feeds medical 
knowledge and clinical practice. 
The main obstacles that have to be overcome towards the evolution of pathologies into 
longitudinal studies, in order to provide enhanced medical knowledge and procedures, are: 
• Clinical protocols are not always standardized and widely accepted 
• Measurements, devices, computational overhead as well as data, may vary 
• Variability in populations participating in the clinical trials 
• Conception of diagnosis and treatment may also vary 
 
Accordingly, the requirements arisen for effective longitudinal studies are: 
• Large studies leading to better statistics and understanding of mechanisms 
• Multi-center approaches that take into account environmental and other factors 
• Availability of evidence-based medicine 
• Sophisticated statistical analysis and modeling 
• Facilitate cooperation among healthcare professionals 
• End-up with protocols, data descriptions, measurement descriptions and models 
 
Adoption of a Grid-based approach in developing pathology follow-up studies may provide: 
• Support and improvement of existing databases import/export facilities 
• Transparent access to data from the user viewpoint, without knowledge of the 
actual data location 
• Authorization policies allowing anonymous and private login for access to public 
and private databases 
• Provision for the privacy of medical information and fulfilment of legal 
requirements in terms of data encryption and protection of patient privacy 
• A wide range of analysis tools, and contribution to the comparison-benchmarking 
of software applications, as well as to the combination of methods supporting 
clinical practice 
• Access to tools and services that support the clinical trials, e.g., real-time 
processing tools, alerting tools for the clinicians, educational services for patients, 
etc. 
• Establishment of common protocols for homogenizing data originated from 
distributed and heterogeneous databases, based on common semantic mechanisms 
• Methods for fetching data based on similarity measures, for example, supporting 
diagnosis in ambiguous cases 
• Common calibration methods for measurements, thus, mechanisms dealing with 
measurements’ variability and ensuring a common understanding of measurements 
and devices 
 Grid on nosocomial infections 
Nosocomial infections are among the three most costly and deadly infectious diseases.  The growth in 
these has continued unabated for nearly two decades, despite many measures – such as shorter 
hospital stays – which can reasonably be expected to have had an attenuating effect. 
A major reason for this growth has been the emergence of antibiotic resistant bacteria.  There are now 
bacterial strains which are resistant to all but one known antibiotic.  It is widely argued that the only 
sustainable defense against this danger is greater vigilance, public education and a significant 
reduction in ‘antibiotic pressure’ in the community. 
Greater vigilance and preparedness are also the only possible defenses against two other modern 
plagues: bioterrorism and various economically catastrophic animal diseases – in the United 
Kingdom, BSE and FMD being cases in point. 
There are several scientific and technical challenges in the design of a Grid epidemiological 
information system.  The typing, i.e. the identification, of bacterial strains is a problem for several 
reasons, among which the multiplicity of typing methods and the difficulty in communication in the 
absence of a universal coding system are significant.  Projects to define a common language often rely 
on one particular method, but there is a need to continue to accommodate new techniques which 
promise greater discrimination.  It is argued that typing of bacterial strains, with the need to search for 
and reconcile fuzzy information across a large number of reference locations, is in itself a suitable 
Grid problem. 
Any strategy to combat antibiotic resistance based on epidemiological insights will have to take 
account of the impact of such factors as levels of antibiotic prescription and of what is known about 
patterns of disease evolution. [7]  In both these areas, provided information is gathered – e.g. about the 
volume of pharmacy-dispensed antibiotic prescriptions – the evidence base on which to determine best 
practice would itself continue to evolve and improve. 
A grid collaboration in the epidemiological control of antibiotic resistant pathogens would require at 
least the following: 
• partnership and integration of knowledge from projects such as EURIS and EARSS; 
• a plausible solution to strain identification as an information problem; 
• coordination of computational efforts to identify and predict patterns of disease propagation. 
 
6.6. DRUG ASSESSMENT 
On the biological and pharmacological side, the determination of allelic frequencies of 
drug target genes in European population is one important application field for a genetic 
epidemiology Grid with large population-based datasets. A second application scenario 
concerns aspects of drug safety; again an aspect that is highly relevant for public health and 
the pharmaceutical industry. Adverse drug effects depend – amongst other factors – on 
cytochrome gene polymorphisms and one of the first large scale study done on a Grid for 
genetic epidemiology could be a project on cytochrome allelic variability in patients with 
e.g. resistance to a certain class of compounds.  
A third application scenario could strive to unravel the genetic basis of drug 
insensitivity which is not based on allelic variation of acute response detoxification genes. 
As an example we might think of the insensitivity of a huge percentage of multiple sclerosis 
patients to treatment with Interferons. Another scenario would concern the insensitivity of a 
significant portion of the European population to treatment with glucocorticoids.  
From the Grid research perspective, drug related epidemiological studies require a tight 
integration of knowledge coming from heterogeneous disciplines, namely pharmacology 
and genetics. Currently, knowledge representations (ontologies) for pharmacology are 
missing by and large; we therefore expect that a Grid on genetic epidemiology that 
addresses aspects of drug action will have to include an activity on ontology construction 
for the domain of pharmacology. A “pharmacology-ontology” would also help to formalise 
and to standardise the description of clinical parameters measured in the course of large 
scale studies. As drug assessment comprises all aspects of pharmacodynamics, special 
attention will have to be paid to appropriate representation of dynamic processes (e.g. 
changes of drug serum concentration over time); sharing of mathematical / statistical 
models for the analysis of drug effects and drug stability will be essential for pan-European 
studies.  
6.7. GENETIC EPIDEMIOLOGY 
The genetic basis of complex diseases provides a real challenge to any information 
system for genetic epidemiology and for a Grid for genetic epidemiology in particular. 
Complex diseases are characterized by the high number of parameters to be recorded and by 
an “intrinsic fuzziness” of the conceptual definition of clinical phenotypes (e.g. 
“depression”). Genetic epidemiology studies in this field require much larger cohorts of 
patients to produce significant results.  
A Grid for genetic epidemiology could have several effects: 
• Homogenisation of the selection of clinical parameters to be measured for the 
analysis of the genetic basis of complex diseases 
• Interoperability of data at both, the data acquisition level as well as the database 
and data management level through structured knowledge representations 
• Broadening of the statistical basis through expansion of relevant cohorts from 
regional or national scale to pan-European scale 
• Interoperability of statistical models and efforts to enrich meta-information on 
analysis tools, algorithms and modelling approaches 
Genetic epidemiology studies try to establish links between genetic variation 
(polymorphisms / allelic variance) and individual risk that have an impact on the quality of 
life (including major diseases).  
Genetic epidemiology studies have a direct impact on decisions on health quality 
standards, disease management and risk assessment. Unfortunately, the prospects of 
Europe-wide genetic epidemiology studies have not yet been fully explored; even though 
significant effort has been undertaken in the course of national projects, data from different 
studies are not easily comparable and data access is very limited.  
A Grid – based system for genetic epidemiology will actually promote the development 
and / or adoption of standards in this field. It will also greatly improve interoperability of 
statistical analysis methods used for the analysis of genetic epidemiological data and it will 
probably allow for new ways to perform data mining approaches in a distributed (data) 
environment. The requirements of Grid – based systems for interoperability, clear semantics 
of data and applications, secure data handling of medical data and administration of virtual 
organisations are extraordinarily high.  
Based on the general considerations outlined above, a Grid for genetic epidemiology 
would have to address the following aspects: 
• clear semantics for data acquisition methods 
• standards for the selection and description of patient collectives  
• standards for patient collective size and statistical power with respect to patient 
collective size 
• an ontology for technologies used in genetic profiling (an ontology similar to the 
microarray ontology generated by the MGED consortium) 
• an ontology for phenotype descriptions based on a relevant controlled vocabularies  
• a dedicated, Grid enabled annotation service for genetic epidemiology  
• data security aspects of biomedical data handling, in particular paying tribute to the 
different European regulations for the handling of patient data 
• interoperability of data analysis methods, in particular a means for declaration of 
statistical methods used  
• capturing of statistical rational applied to patient collective selection  
• capturing of rational for candidate gene selection  
• capturing of rational for the selection of chromosomal regions  
• declaration and brokering of statistical analysis services  
• Grid based statistical modelling and data mining 
• Grid based evaluation of existing relevant literature (including electronic patient 
records) by means of automated information extraction methods (text mining). 
Substantial effort on open standards, capturing and formalisation of statistical 
considerations relevant for patient collective selection and controlled vocabularies / 
ontologies is needed. The scientific benefit of such effort, however, would be paramount: 
• Data from national and European genetic epidemiological studies would be 
comparable at different levels, ranging from sample acquisition and sample 
treatment protocols to the rationale for patient stratification and suitable statistical 
analysis approaches 
• Standards for the description of clinical parameters would be established; the 
semantic relationship between parameters would be clear and consequently 
comparability of genetic epidemiological studies based on conceptual equivalence 
at different levels would be possible 
• Interoperability of statistical models and analysis methods would be greatly 
enhanced; rational capturing for statistics would become a routine procedure 
• Conclusions drawn from genetic-epidemiological studies could be re-analysed and 
re-tested with each new (equivalent) study. 
• Parameters influencing e.g. the prevalence for certain tumour types in certain 
regions within the EU could be identified with a much higher chance. Effects 
influencing genotype-phenotype associations such as nutrition habits, behavioural 
differences, quality of health services and so forth could probably be quantified 
with much better significance. 
• Variability of associations between genes and phenotypes could be assessed at the 
European level, which means that the genetic heterogeneity within Europe would 
open new perspectives to define “control groups” in statistical meta-analyses.  
For a Grid for genetic epidemiology we foresee a key role for Grid services that refer to 
established controlled vocabularies and ontologies. 
A problem particular to this field is that it suffers from the complicated and very 
complex phenotype descriptions necessary to describe e.g. depression in terms of 
quantitative parameters. This problem is very serious; current discussion of future trends in 
genetic epidemiology of complex diseases already foresees that this field of science is 
running the risk to become too expensive to be continued in the way this science has been 
done in the past. [8] A Grid for genetic epidemiology will provide a first means to make 
data and tools interoperable at the European level; ultimately such dedicated Grid will help 
to limit the costs of genetic epidemiology research in the field of complex diseases. 
 
Examples of epidemiology Grids are: 
• Genetic epidemiology Grids for the identification of genes involved in complex diseases  
• Statistical studies: work on populations of patients. One example is the tracking of resistance to 
therapeutic agents.  This is most notable in relation to antibiotic resistance in common bacteria in 
nosocomial and community settings 
• Drug assessment: drug impact evaluation through populations analysis 
• Pathology follow-up: pathologies evolution in longitudinal studies 
• Grids for humanitarian development: Grid technology opens new perspectives for preparation and 
follow-up of medical missions in developing countries as well as support to local medical centres in 
terms of tele-consulting, tele-diagnosis, patient follow-up and e-learning. 
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7. Genomic Medicine and Grid Computing 
The full realization of the Genomic Medicine concept, in which genomics and 
proteomics are used to empower healthcare, requires the integration of knowledge from 
worlds traditionally apart, specially biology and medicine. To harness effectively the wealth 
of information available in research centres and care facilities, a new framework of 
computer methods and tools must be in place, bridging medical and bio informatics. 
In such an approach, all levels of information – from the molecule to the population, 
through the cell, the tissue, the organ and the patient – and the most appropriate techniques 
and methods would be used.  Some would come from bioinformatics and others from 
medical informatics or even public health or epidemiological informatics (cf. Table 1). 
7.1. DEVELOPMENTS IN GENOMICS AFFECTING CARE DELIVERY 
The completion of the Human Genome Project (HGP) is seen for medicine as a source 
of new knowledge to understand the relationships between the structure of human genes, 
environmental factors and physiopathological processes [1]. In the post-genomic era, the 
possibility of studying all the genes, all the proteins or a high number of mutations in 
human cells paves the way to hitherto infeasible research methods to understand the 
molecular basis of complex diseases and so to facilitate the development of new diagnostic 
and therapeutic solutions [2].  
Genomic medicine will impact care provision in different ways: 
Clinical diagnosis: New high-performance research devices (biochips) make it possible to 
monitor simultaneously a large number of parameters that can be used as diagnostic 
markers. Genetic analyses are used to identify individuals who are likely to contract a 
disease, as well as to confirm a suspected mutation in an individual or a family, before 
any associated symptoms appear [4]. Proteomics will also offer new markers of interest 
for patient monitoring [5]. 
Disease reclassification: Comparison of different gene expression profiles between healthy 
cells and those that come from a diseased tissue allows in some cases the identification 
of different molecular shapes and the proposal of new classifications for the diseases, 
which will allow an improvement in their diagnoses and prognoses.  
Pharmacogenetics and Pharmacogenomics: In the last few years, successful 
technological methods have been developed to study and apply individual variations on 
a molecular scale. New technologies that aid our understanding of the role of genes in 
diseases are providing the industry with substantial opportunities of more powerful 
medicines, safer drugs and better vaccines (pharmacogenomics) [6].  
Genetic epidemiology and Public Health: The use of new genetic information 
technologies will make it possible to perform cost-effective screening (genetic tests) at 
the population level [7]. To transfer genomic knowledge to the field of public health 
and epidemiology, it will be important to develop efforts in associative genetics, in 
genotype-phenotype population studies, and in programmes to disseminate genetic 
information and to train health workers.  
Current research on genomic medicine is producing an enormous volume of data, 
requiring distribution resources to make it available worldwide and advanced computational 
tools to analyse it [8].  
7.2. THE CONVERGENCE OF BIO- AND MEDICAL INFORMATICS 
The term ‘biomedical informatics’ is increasingly being used in conferences and 
articles, indicating the space where the disciplines of medical informatics and 
bioinformatics meet and interact. 
State of the art methods in bioinformatics include internet data banks, from which the 
whole scientific community can benefit. However, present informatics tools appear to lack 
the necessary methods and features effectively to link genetic and clinical information and, 
beyond those, existing genetic databases and their possible health applications [9]. 
Information management tools are necessary to convert the enormous amount of data 
that geneticists and molecular biologists can obtain at their labs in information that 
physicians and health workers can use. The challenge now is to find the appropriate 
technologies to transform biomedical breakthroughs into shared knowledge, facilitating 
diagnostic and therapeutic solutions. 
Though it is currently difficult to predict the health problems that a single gene or 
protein mutation can produce and how to translate that knowledge into new clinical 
procedures, it is clear that genes interact with many other genes and environmental factors. 
Only combined studies of gene interactions in humans and other animals and large 
epidemiological studies from many different populations can reveal the complex pathways 
of genetic diseases.  
Progress in the understanding of the genetic code, gene products and functions, is 
elucidating the mechanisms underlying diseases. The holistic view of a person’s health is 
built up from the integration of different sources of knowledge, combining both clinical and 
genetic information. Biomedical information resources available to researches and 
practitioners include patient data and conditions, genome and sequences, protein sequence 
and structure, mutations, genetic diseases, genetic tests, terminology and coding systems, 
patient counselling resources, and more.  
Navigating between phenotype and genotype in clinical settings means that genetic 
assessment will be integrated in patient investigations. This vision requires the design and 
implementation of computer methods and tools to deliver effective platforms for seamless 
biomedical data association. The integration of biomedical knowledge resources brings up a 
new problem domain with some specific challenges to be addressed: 
• There are many different sources of information spread over the web; the relevant 
information needs to be modelled, discovered, accessed and retrieved. 
• Data integration is difficult since databases can present a wide range of formats 
and different semantics. In addition, public information resources are often only 
available through web interfaces, not easily interrogated by computer applications. 
• Coding and terminologies are not unified, so that it is sometimes difficult to 
discern quality and link related concepts. Gene naming, for example, is far from 
being unified.  
• Medical coding systems are not ready to manage the emerging genetic information. 
• Intellectual property rights, privacy and confidentiality issues and protection of the 
ownership of valuable data may hinder the exchange of contents. 
• Results are often published in natural language formats (scientific bibliography), 
requiring mining techniques to recover the knowledge in computer ready 
representations. 
• The amount of data available and being produced is tremendous, requiring high-
performance computer storage, processing power and networking infrastructures to 
ensure that it is effectively communicated, managed and exploited. 
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Table 1: Synergy between medical informatics and bioinformatics to 
build broader views and raise opportunities in health informatics (cf. [10]) 
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Figure 1: A conceptual framework for the study of genetic disorders. 
This figure illustrates a possible protocol to guide a researcher or practitioner on obtaining pertinent 
information on a disease, as follows: A professional would start by searching by pathology name. This 
search could be performed on the OMIM database, publicly available on the Internet. The pathology is due to 
a mutation (information available at OMIM) or to a polymorphism or SNP (information available at 
dbSNPs). SNPs are within a nucleotide sequence (RefSeq) which in turn is in a gene (Genecards). This gene 
has a chromosomal localization (LOCUSLINK), an approved name (HGNC) and a molecular function 
found within Gene Ontology (GO). The gene codes for a protein, a sequence of amino acids (SWISSPROT). 
The sequence determines the structure of the protein (PDB). The protein is classified into protein domains 
(InterPRO) and has a functional site (PROSITE). Proteins have enzymatic properties (ExPASY-ENZYME) in 
metabolic pathways (KEGG). Drugs are chemical compounds (Orphanet) that are developed through 
pharmacogenetic research (PharmGKB) and validated in clinical trials (ClinicalTrials.gov). Most of the 
entries described can directly link to bibliography in life sciences (PubMed). 
7.3. SEMANTIC INTEGRATION OF BIOMEDICAL RESOURCES 
Biomedical resources are usually unrelated to each other, though the contents they hold 
are strongly and semantically connected. Bringing together such knowledge is a complex 
task, since it is difficult automatically to make the semantic connections. 
The semantic integration of such resources would be one of the enabling factors to 
promote the deployment of novel biomedical applications involving research-oriented 
competence centres, specialized core facilities and laboratories (such as micro-chip array, 
mass spectrometry, etc.), and health centres where clinical guidelines are applied, such as 
hospitals. The main goals of semantic integration of biomedical resources are: 
• to allow coherent access to biological, biomedical, bioinformatic, medical and clinical 
resources, especially data sources, such as bioinformatics data banks (e.g. SwissProt, 
Protein Data Bank - PDB) and Electronic Patient Record systems (EPR) [11]; 
• to facilitate the discovery and exploitation of intra- and inter-data source semantic 
relationships (e.g. a protein sequence in SwissProt is related to a protein secondary 
structure in PDB or a 3D shape of a protein in PDB can be bound to a drug compound 
of a ligand database).  
The semantic integration of biomedical resources can benefit from existing standards, 
applying emerging knowledge management and modelling methodologies and technologies, 
such as Data and Text Mining, Document and Content management systems, ontologies, 
relational databases, semi-structured databases, modelling languages, and metadata 
management. The main services that compose semantic integration framework include: 
• semantic modelling of different biomedical concepts and resources using ontologies 
(such as GeneOntology [12]) and metadata; 
• semantic annotation of biomedical resources, to allow a continual knowledge exchange 
between data sources and users (researchers, doctors, physicians, etc.); 
• discovering, browsing and querying of biomedical resources, offered both to human 
users and to computer programs, driven by semantic concepts other than keywords; 
• semantic modelling of medical documentation through different types of metadata: 
media-type dependent, content-descriptive, content classification, document 
composition, document history, document location.  
Recent advances in grid technology are in line with semantic integration needs. 
Emerging grid infrastructures include: 
• Web services that allow the discovery, invocation and execution of distributed services, 
and could be used to implement some basic biomedical services and applications;  
• Grid-based DBMSs and metadata management systems. In order to provide a secure, 
efficient, and automatic data source management in a Grid environment a new concept 
can be introduced: the Grid-DBMS [13].  
• Support for Virtual Organization clusters through basic Grid services, such as security, 
and tools and platforms for cooperation. 
Semantic integration involves both modelling and technology. While the former allows 
for the deployment of high level semantic services and applications, the latter can enhance 
performance and efficiency on distributed and Grid environments. 
7.4. BIOMEDICAL GRIDS FOR HEALTH APPLICATIONS  
Many research and development areas of informatics are needed to support genomic 
medicine, including the development of models and digital simulations, molecular imaging, 
global scale data access and association, etc. [14]. Grid technology is among these and can 
contribute to the development of some key areas by (1) supplying high computing power, 
(2) enabling seamless access and integration of complex and distributed data sources, and 
(3) establishing collaborative Virtual Organizations in order to enhance human-to-human 
interactions [15] [16]. 
Expected contributions of grid technologies to the realization of genomic medicine 
include: 
1. Computational genomics and proteomics in the identification of genes and proteins, 
automatic annotation and characterization of genetic individual variations (e.g. virtual 
laboratories of genetic information) 
2. Technologies to store large amounts of phenotype, genotype and proteotype data in 
meta-relational databases. 
3. Support to the development of clinical trials.. 
4. Provision of personalized healthcare services through genetic profiling of patients, 
understanding heredity, coherent clinical observations, epidemiological studies, and 
statistical analysis.  
5. Development of models and digital simulations of cells and diseases. Link gene 
expression patterns with disease models to uncover pathogenic pathways related with 
the patient’s clinical condition, life-style, nutrition, and genetic disposition. Ubiquitous 
access to the whole history of health of a person, independently of the centre where 
there has been gathered information of the clinical episodes. 3-D models (of the body, 
cells, etc), combining anatomic and functional parameters, can be built to implement 
metabolic pathways and processes, linking structural information with cell assembly 
information. With the appropriate computer resources, gene sequences, functions, 
pathophysiological processes and clinical manifestations could be progressively 
integrated in a unified abstraction. This functional model could provide biomedical 
researchers and health educators and professionals with a reference for their routine 
work. These systems will be used in the assessment of the effects of a toxic agent or of 
the action that a given drug triggers in the cellular response against a disease. (e.g.: 
[17]). 
6. Providing tools to support physicians’ training and to improve biomedical knowledge 
management. Most physicians have only a rudimentary understanding of genetics and 
genomics. E-learning tools may be decisive by introducing an easy and rapid means to 
adopt new methods and new perspectives in routine work and the adoption of genomic 
medicine. These collaborative e-learning tools would share computational resources 
such as data files and simulations and are themselves candidates to exploit grid 
technology, e.g. to integrate and share features. Thus a goal must be to provide e-health 
portals, oriented towards the resolution of problems by use of distributed applications. 
 
7. Molecular imaging.  The new field of functional and molecular imaging arises from 
the combination of medical imaging technologies with genomic approaches. This area 
can increase the diagnostic arsenal by means of in vivo visualisation of cellular and 
genetic processes. Molecular imaging developments pursue quantitative and non-
invasive studies of diseases at the molecular level. Grid can provide the processing 
power needed in this area. 
8. Genetic epidemiology. Population studies may be undertaken in which the influence of 
environmental and genetic factors in particular diseases are explored. The information 
sources needed to perform such studies are spread in different and remote sites. Grid 
infrastructures can facilitate seamless access to all these resources.  
9. Development of Pharmacogenomics.  Drug design can be revolutionized through the a 
new reasoned approach using gene sequence and protein structure function information 
rather than a traditional trial-and-error method. A new generation of data models and 
repositories will be needed to handle the complex spectrum of information sources 
needed in these approaches (laboratory measures, clinical findings, human genetic 
variation, chemical compounds, and metabolic pathways).  Grid offers services that 
assist in the management of this diversity of information sources. 
10. Developing tools that support clinical decision making, combining multiple relevant 
information sources (genetic, clinical and environmental). In a genomic medicine 
framework, medical practitioners will access biological information and integrate it 
with data included in computerized patient records or departmental systems in large 
hospitals. Grid could help to integrate all the data used in decision-making and to build 
the computing power needed to run real time, complex interactive systems. 
11. Integrating databases and knowledge between the clinical world and that of genomic 
research. Biomedical research is a collaborative science, in which multidisciplinary 
teams join skills and resources. Often, this research comprises multiple institutions and 
sets up virtual organizations. Partners engaged in biomedical research need a 
computational infrastructure that can support this kind of collaboration and sharing of 
information systems, often ‘legacy’ systems, heterogeneous and decentralized. In 
addition, progress in life sciences depends on the ability to develop common 
representations (ontologies, integrated vocabularies, etc.) to model and describe 
heterogeneous information. The challenge is to adapt existing systems or to develop 
new ones that allow the exchange and integration of data. Grid, enhanced with semantic 
integration services, can help not only in the sharing of computer resources, but also to 
integrate genetic data obtained from functional and comparative (individual) genomics 
into clinical information systems. 
7.5. REQUIREMENTS AND ARCHITECTURES OF BIOMEDICAL GRIDS 
The way data at different levels of the grid can be effectively acquired, represented, 
exchanged, integrated and converted into useful knowledge is an emerging research field 
known as “Grid Intelligence” [19]. In particular, ontologies and metadata are the basic 
elements through which Grid Intelligence services can be developed [20]. Using ontologies, 
Grids may offer semantic modelling of user's tasks/needs, available services, and data 
sources to support high level services and dynamic services finding and composition. 
Moreover, data mining and knowledge management techniques could enable novel services 
based on the semantics of stored data. Semantic Grid focuses on the systematic adoption of 
metadata and ontologies to describe grid resources, to enhance and automate service 
discovery and negotiation, application composition, information extraction, and knowledge 
discovery [21]. Knowledge Grids [22] offer high-level tools and techniques for distributed 
mining and extraction of knowledge from data repositories available on the grid, leveraging 
semantic descriptions of components and data, as provided by Semantic Grid, and offering 
knowledge discovery services.  
Biomedical Grids must be able to produce, use and deploy knowledge as a basic 
element of advanced applications and will be mainly based on Knowledge Grids and 
Semantic Grids. Leveraging their high level services, it will allow delivery of information, 
knowledge, medical guidelines, and research results in an applicable form to the right user, 
in the right setting. The Cancer Biomedical Informatics Grid (caBIG), a cancer-based 
biomedical informatics network developed by the National Cancer Institute 
(www.nci.nih.gov), goes along this direction. caBIG will connect cancer related data 
sources, tools, individuals, and organizations, and will help redefine how research is 
conducted, care is provided, and patients and participants interact with the biomedical 
research enterprise (cabig.nci.nih.gov/caBIG/overview/).  
Biomedical Grids may help in storing, integrating, and analysing the data produced or 
used (e.g. provided by public databases) in the experiments and research activities. 
Moreover, they will support the modelling, designing and execution of workflow 
experiments (e.g. “in silico” experiments), by using standard modelling techniques such as 
UML, ontologies, and workflow languages. Main conceptual layers of Biomedical Grids 
include: 
• Data sources and modelling layer. The data sources, comprising data produced during 
experiments (e.g. mass spectrometry, microarray, and so on), data provided by public 
databases (e.g. PDB, SwissProt), and data coming from clinical practice, need to be 
modelled using well established and novel knowledge management methodologies, 
such as UML and ontologies. Data sources need to be integrated and federated to allow 
easy access to specific information or to data semantically correlated. Main tasks of this 
layer are: ontology-based modelling of biological/biomedical databases; modelling of 
distributed biomedical applications, such as in-silico experiments. The modelling 
should comprise all phases of experiments, such as sample preparation, data generation, 
data pre-processing and filtering, images analysis, bioinformatics analysis, bio-medical 
analysis, results visualization [23]. 
• Application composition and enactment layer. This workflow composition layer makes 
it possible to realize complex bioinformatic and biomedical applications (e.g. in silico 
experiments) by composition of basic (open source) bioinformatics tools, that will be 
executed on the grid, exploiting the resources and data provided by research centres 
forming different Virtual Organizations. Useful software tools need to be classified in 
the modelling layer of the platform, with respect to technology and use aspects. Key 
issues of this layer are: domain ontologies to model (open source) bioinformatics 
software components, and public available biological databases; ontology-based 
querying and browsing on domain ontologies for the discovery, selection, and location 
of bioinformatics and biomedical resources (data and software components), to be used 
in the composition of applications; workflow-based modelling and scheduling of 
distributed applications on the Grid; extensive use of Open Source software 
components and components provided by the research centres. 
• Data analysis and knowledge extraction layer. In this layer advanced data analysis 
tools, composed using the workflow technologies, allow the extraction of knowledge 
useful for prosecuting experiments. This layer should comprise a set of data analysis 
plug-ins using different methodologies and approaches, for example: statistical analysis 
and data mining; survival analysis and other temporal data analysis; visualization of 
multidimensional data; classification of data, and so on (e.g. KNOWLEDGE GRID [22], 
PROTEUS [24]). 
7.6. THE ROAD AHEAD FOR GRID-ENABLED GENOMIC MEDICINE 
Grid is an emerging technology, still in its infancy. The road ahead is uncertain, but it is 
possible to set up a very general roadmap for its successful application in the area of 
genomic medicine. Some of the required steps include: 
1. Developing the specific semantic grid services required for a knowledge integration 
environment. 
2. Deploying and testing the first grid middleware prototypes for the health sector 
(research and care provision). 
3. Developing, deploying and testing the first grid genomic medicine applications. 
4. Fostering and promotion of the grid culture by means of the education and training of 
the physicians, scientists and other  staff involved in genomic medicine.  
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8. Healthgrid Confidentiality and Ethical Issues 
In healthcare, patients’ sensitive personal data is recorded and used. This implies a need 
for strict confidentiality and enforced protection of privacy. These requirements have not 
previously been dealt with in grid technology, as a consequence of the fact that in High 
Energy Physics, the root of much grid technology, elementary particle data needs no 
privacy protection, unlike humans in a modern society. 
Biomedical data often includes very sensitive information about a subject and although 
generally used for the benefit of the community, this information is still prone to abuse. 
There is appropriate concern about the proper treatment of sensitive data. Incidents of abuse 
have been previously reported in the public media [L03], proving that the threat is genuine. 
Consider, for example, the impact on society if banks, insurance companies and employers, 
could access healthcare data about their customers, revealing past, current, and probable 
future health status. Indeed, abuse of medical data can affect all of us, as at some point in 
life practically everyone has to complete loan, insurance or job applications. 
It is clear that privacy protection directly impacts personal well-being as well as society 
as a whole. Indeed, some go as far as to believe that failure to protect privacy might lead to 
our ruin [C03]. Privacy is recognized as a fundamental human right. Public authorities are 
sharply aware of these repercussions, and they are putting considerable effort into privacy 
protection legislation [EU95][EU02]. Because of the possibilities opened up by modern grid 
technology (such as trans-border processing of sensitive data), studies regarding legal 
constraints in a healthgrid are of great importance (see Chapter 9). 
Medical practice and research have always adhered to strict ethics. These domains are 
accustomed to supervision by (ethical) institutional review boards which enforce such 
requirements as obtaining informed consent from patients [M01]. Scientists and technicians 
developing grid technology are often unfamiliar with concerns about the proper treatment of 
information, but healthcare professionals are very conscious of this requirement. The 
privacy and legal issues raised by healthgrids mainly arise through the transparent 
interchange and processing of sensitive healthcare information, resulting from the aim of 
removing the line between local and remote resources with grid technology. These 
problems are certainly not entirely new to medical informatics. It is therefore of utmost 
importance that experts share their experience on security and privacy related issues in 
healthcare, in order to avoid that these become barriers for the realization of the healthgrid.  
8.1. PRIVACY PROTECTION, SECURITY AND THE HEALTHGRID 
8.1.1. Grid Security Technology 
From the very start, the grid community has put a lot of effort into the design of 
security measures [W03]. Authentication and authorization mechanisms are the main 
point of focus of these developments, as they are the most basic of security measures. 
Integration at the level of the lower middleware allows security mechanisms to be uniform 
(developer APIs) and interoperable (cf. [GLOBUS]). Implementation is still at an early 
stage. It is important to realize that the further development of security technology is key to 
the acceptance of the healthgrid concept. 
Avoiding unauthorized access to sensitive data is the first level of confidentiality 
protection. In healthcare, state-of-the-art security solutions have always been used. An equal 
level of protection will be demanded from a grid environment. Any healthgrid initiative 
should therefore be aware of the latest security developments in the grid community. 
Development of basic services, such as for example integration on a lower middleware level 
of fine grained access control (e.g. provided by CAS or VOMS grid solutions), should be 
encouraged by the biomedical community.  
A specific healthgrid initiative should enable the further development and testing of 
these security mechanisms, beyond the point where classical grid developers may stop, 
believing that for their application sufficient measures are already in place. 
The security technology currently present in the grid community might even offer a 
sufficient solution for the first and most obvious healthcare applications: computational 
problems in healthcare. Deployment of computational grids in healthcare is a reasonable 
first step towards a true healthgrid – though it is only a first step. The problems faced there 
are similar to the ones encountered in more classical grid domains.  
Unlike many other areas of healthcare, confidentiality in such cases is usually of 
secondary importance. The nature of the application itself reduces the risk of disclosure of 
sensitive information. Computational challenges inherently segment the processed data and 
typically only deal with non-identifiable data related to complex computational models. 
Thus, the similarity with classical grid applications persists also in the security domain, 
there is no real need for specialized ‘information security’. 
8.1.2. Healthgrid Security Requirements 
Healthgrid will not restrict to the use of grid technology for distributed computing only. 
Eventually, healthgrid should offer a generic platform for all e-health actors. Hence, thye 
sharing of large amounts of distributed heterogeneous (on various levels) data is also an 
important issue. 
It is clear that linking several distributed data sources bound to a single individual on a 
data grid opens of up a range of privacy risks. The (virtual) federation of a large amount of 
personal medical data is not the only risk at hand. Grid technology will undoubtedly further 
stimulate the use of genomic data in research. However, this particular type of data has a 
number of specific characteristics related to privacy which are not found in any other type 
of (medical) information: 
• Genetic data not only concerns individuals, but also their relatives. A person’s 
consent to release his or her genetic information constitutes a de facto release of 
information about other individuals, i.e. his or her relatives. In the case of genomic 
medicine, there is a complex interaction between individual rights and collective 
requirements. 
• Medical data deals with the past and current health status of persons, but genetic 
information can also give indications about future health or disease conditions. 
• An individual person’s genotype is almost unique and stable; hence it can become 
the source of an increasing amount of information. 
• The full extent of the information included in the genomic data is not known yet; 
hence it is difficult to assess the full extent of disclosure. 
• Genomic data is easily wrongly interpreted by non-professionals; ‘susceptibility’ to 
diseases can easily be mistaken with certainty of illness.  
The above clearly indicates the need to reconcile two seemingly conflicting objectives: 
on the one hand, the maximization of healthcare opportunities and of medical research 
productivity and efficiency in data handling; on the other, the protection of the human 
(privacy) rights; this is the challenge at hand. 
A couple of basic approaches to safeguarding confidentiality have been identified in the 
past in healthcare practice. The first approach focuses on the creators and maintainers of the 
information, prohibiting them from disclosing the information to inappropriate parties. 
Basically, this comes down to the deployment of classical security measures (access 
control, authorization). A healthgrid initiative is ideal for the further development (and 
actual implementation) of grid security technology, because of the strict requirements in 
healthcare. A first task within the healthgrid context could thus be performing an in depth 
analysis of the new and specific risks and threats that arise. 
8.1.3. Privacy Enhancing Technology 
Technology which is specifically designed to safeguard privacy is generally referred to 
as Privacy Enhancing Techniques or Technologies (PETs). According to one author, PETs 
can be described as [B01]: 
‘A coherent system of ICT measures that protects privacy by eliminating 
or reducing personal data or by preventing unnecessary and/or undesired 
processing of personal data, all without losing the functionality of the 
information system.’ 
Privacy Enhancing Technologies are fairly new – the concept has only been around 
since the ’90s – and have been extensively researched in both the USA and in Europe.  
In healthcare, PETs are mainly used for privacy protection of persons included in 
medical data collections. The goal of these PETs is to guarantee anonymity of data subjects 
while making information available for clinical practice and research. The use of such 
techniques in healthcare has been demonstrated in several research projects [DC02] and 
solutions are already commercially deployed, in clinical trials, disease studies, for the 
exchange of research data and for the daily handling of sensitive data. PETs such as 
anonymization have already been considered for standardization (introduced as a working 
item in CEN/TC251). 
For healthgrid, access to large amounts of useful, personal information can be unlocked 
though the use of privacy protection techniques (mainly de-identification methods) [DC04]. 
8.1.4. Grid Integration of PETs and Security 
Security and privacy protection techniques are closely linked. Emphasis of the latter 
however lies on limiting the identifiable information content of the data rather than on 
merely restricting access to the data itself. Although the strict difference between the two is 
not always clear, Privacy Enhancing Technology and security technology should be 
regarded as complementary in safeguarding the confidentiality of personal information.  
The question whether these specific security techniques and privacy protection 
measures should be integrated in the healthgrid itself, is a valid one. It is beyond doubt that 
all healthgrids need to take into account the stringent data protection requirements of the 
healthcare sector. However, these measures could be implemented completely separately 
from the grid nature of an application. In that case there would be little difference with 
current ad hoc solutions (privacy-aware health data collection unrelated to grid technology). 
On the other hand, the integration of specific privacy protection solutions into grid 
services could offer considerable advantages. Integration is not only logical because of the 
close relationship with classical measures (which are largely part of the grid middleware), 
but can also stimulate the use of privacy protecting technology leading to data protection 
‘by default’ in each healthcare related grid application. Integration of PETs into the lower 
middleware level should probably be limited (in that context, see further, policy 
management). Lower middleware (such as Globus) aims at providing a broad generic 
toolbox for grid development. Specific biomedical informatics security and privacy are not 
a primary objective for middleware developers. 
Just as in several data integration initiatives, healthcare specific security and privacy 
solutions could be offered at an upper middleware level, combining the advantage of still 
being generic (at the disposal of a wide community), but not overloading the toolset for 
other areas of research which do not need such strict measures.  
The main part of privacy protection measures will, at least in the beginning, be situated 
at the application level. This does not imply that development is beyond the scope of a 
healthgrid initiative. On the contrary, next to the fact that stringent data protection is a 
prerequisite for healthcare IT, standardization of PET technology can be encouraged by the 
development of specific grid services, such as a policy-driven pseudonymization service 
which allows centres automatically to de-identify their databases through a grid service 
(guaranteeing use of the latest technology) before exchanging information with another site.  
As developments and pilot projects progress, it will become clear which piece of 
technology should be implemented at what level. 
8.1.5. Healthgrid Issues 
In order to illustrate the need of specific research in any healthgrid initiative, some 
typical problems due to the strict requirements of the medical world will be given. The 
examples presented here are fairly straightforward and thus have been identified before 
[GK02]. However they have not been adequately dealt with. With the introduction of a 
healthgrid, the need for confidentiality and data protection is more pressing than ever. 
The grid promises access to heterogeneous resources, so that in a healthgrid remote 
resources will be storing and processing sensitive personal data. These resources should 
thus be trusted by the end-user. But who can be the judge of ‘trustworthiness’ of a grid 
resource? A simple and straightforward solution is to use ‘closed’ systems, which means 
that any resource in the grid is well known and specified in advance. This however conflict 
with the vision of a dynamic grid, in which links are established as necessary. 
Solutions should rather be sought in the area of policy advertising and negotiation. 
Resources should be able to inform a candidate user on how the data will be treated, which 
policies are applied, what PETs are used, who can have access to the data, etc. These 
methods are sometimes said not to be genuine PETs, since they do not limit collection of 
personal identifiable data and do not give any guarantees about the actual processing. A 
resource can claim to adhere to strict rules, but in practice this can not be verified. 
The first steps in the direction of policy management have already been taken by grid 
developers. The development of standards such as WS-Privacy, WS-Policy and Enterprise 
Privacy Authorization Language (EPAL) is an effort in that direction, but implementation to 
date is rather limited, and the full possibilities of the technology will not be researched 
unless it is in the healthcare area – the main application domain. A healthgrid would be the 
ideal environment where such PETs could be tested and further developed. 
These considerations directly impact typical grid mechanisms, such as data replication. 
Replication mechanisms automatically copy data on a resource in order to increase 
efficiency (e.g. to avoid transfer delays). With medical data, this may not be permitted. The 
site on which the data will be replicated should at least be as trustworthy as the data source 
and should adhere to the same strict policies. A healthgrid should be able to handle such 
cases autonomously in order not to lose its dynamic nature (and efficiency). 
Another example is delegation. Delegation of rights is fundamental in a grid 
environment, but in the medical world, this is far from obvious. If one passes on rights to 
others (resources), one becomes liable for actions performed on one’s behalf. In a healthcare 
environment this has serious implications in terms of liability. Restricted proxy certificates 
offer a path to a solution suitable for medical applications, but clearly need to be extended. 
Policy management will be an important topic in healthgrid, both for security (e.g. 
authorization policies) as for data protection (privacy policies). A difficult problem in this 
context is the one of policy enforcement and assurance. 
Equally important and closely related to this subject, is the implementation of auditing 
mechanisms. All actions in a medical context should be logged in a trustworthy way. Non-
repudiation combined with a legal framework could help solve liability issues in healthcare. 
Next to the areas of interest mentioned in this text, there are several other healthcare 
needs for grid applications which could be developed at, e.g., upper middleware level for 
the benefit of a large community within a healthgrid context. Among these are encrypted 
storage for medical data (a far from obvious problem) and trustworthy federation of 
research databases – virtual federation of small ‘cells’ of de-identified data (e.g. 
geographical area or hospital) can decrease the re-identification risk (by increasing the 
anonymity set). Finally a range of PETs which are well suited to distributed environments is 
emerging – Private Information Retrieval and Storage (PIRS) which includes privacy-
preserving data mining, processing of encrypted data, and other related technologies. 
However the road to an advanced generic privacy preserving framework for e-health is still 
long and littered with technical difficulties which will have to be tackled one at a time. 
It is however a fact that grid technology can only be successful in a biomedical 
environment if the ethical guidelines and legal requirements are adequately met by 
technological solutions which are continually evaluated and updated as new needs arise. 
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9. Healthgrid from a Legal Point of View 
The introduction of grid technology in the health care sector may appear to be only of 
technical significance and, in any event, without any legal relevance. It appears only to 
concern a new computing technology participating in the provision of healthcare services 
and in scientific research, mostly by providing huge computing and memory resources, 
possibly internet based.  The first projects deal with medical imaging, medical tele-
assistance, medical or pharmaceutical research, human genomic studies, and the creation of 
databases for therapeutic, scientific, statistical or epidemiological purposes. 
However these projects are ruled by radically different legal contexts. Indeed, distinct 
legal rules govern the practice of medicine, scientific and pharmaceutical research, 
epidemiological studies, even if all these disciplines contribute to medical progress. 
Hence there is no unique answer to the determination of the legal framework in which 
healthgrid technology may be implemented and used. In reality, the answers are multiple 
and depend on the context of each project as well as on the considered legal viewpoints. 
Healthgrid technology must conform to the legal context specific to each project aiming at 
its implementation. 
Nevertheless describing the different legal contexts in which healthgrid technology 
might be implemented is not sufficient. The adequacy of the legal context coupled to the 
characteristics of this particular technology should also be evaluated. In other words, one 
should question whether certain rules should not (have to) be adapted with respect to 
healthgrid technology. 
9.1. HEALTHGRID TECHNOLOGY’S STATUS 
Technologies must frequently comply with precise technical norms with a view to their 
legal utilization. The same assertion is also valid for the health care sector. It is therefore 
important to define the content of the technical norms relevant to each project. 
In this matter, some technical norms have been harmonized at an international or 
European level. With respect to this, it is useful to note that the European Committee for 
Standardization has issued a very interesting study entitled “European Standardization of 
Health Informatics – Results of the mandated work by CEN/TC 252” (CEN TC 251/N01-
024 – 2001-06-17). 
The European Union has also adopted several rules concerning medical devices: 
• Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws 
of the Member States relating to active implantable medical devices. 
• Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. 
• Directive 98/79/EC of the European Parliament and of the Council of 27 October 
1998 on in vitro diagnostic medical devices. 
It is hence required in each project to: 
• determine the technical norms applicable to healthgrid technology in the project 
under consideration, depending on the national legal orders likely to rule it ; 
• verify the adequacy of these technical norms.  
The Council of Europe states that the improvement of human life quality and the 
respect of human rights should prevail when dealing with new technologies. It namely 
recommends in this regard that the precise evaluation of any technology should as much as 
possible rely on the following criteria (cf. Recommendation (90) 8 of 29 March 1990 on the 
impact of new technologies on health services, particularly primary health care): 
• Validity of outputs, 
• Validity of data capture, 
• Ability to fit within the framework of primary health care, 
• Social acceptability, 
• Ethical acceptability, 
• Professional acceptability, 
• Reliability, 
• Capacity for continuous assessment, 
• Safety for providers, consumers and the environment, 
• Cost effectiveness compared to older technologies, 
• Availability of full information on the technology and experience in 
implementing it, 
• Protection of confidentiality, 
• Ability to be integrated smoothly into existing systems, 
• Availability of adequate resources. 
This evaluation should consist of appropriate studies giving conclusive results, and 
should be carried out prior to the general introduction of any new technology. 
9.2. STATUS OF THE PROCESSED PERSONAL DATA 
Most of healthgrid technology-related projects imply personal data processing for 
therapeutic purposes or scientific research (e.g. medical imaging, tele-assistance, medical or 
scientific research, human genomic studies, creation of healthgrid databases). 
However personal data processing is subject to numerous regulations. Indeed, these 
data are particularly sensitive and consequently require high protection. Furthermore, 
because of the therapeutic or scientific stakes, personal data processing must be reliable, or 
it may lead to medical errors or erroneous scientific results.  
On the international level many norms govern personal data processing (including the 
processing of personal data related to health). 
Article 8 of the Convention for the Protection of Human Rights and Fundamental 
Freedoms is particularly to the point in this respect. 
In the case M.S. v. Sweden of 27 August 1997 (74/1996/693/885) (§ 41), the European 
Court of Human Rights vigorously stated that “(…) the protection of personal data, 
particularly medical data, is of fundamental importance to a person's enjoyment of his or 
her right to respect for private and family life as guaranteed by Article 8 of the Convention. 
Respecting the confidentiality of health data is a vital principle in the legal systems of all 
the Contracting Parties to the Convention. It is crucial not only to respect the sense of 
privacy of a patient but also to preserve his or her confidence in the medical profession and 
in the health services in general. The domestic law must afford appropriate safeguards to 
prevent any such communication or disclosure of personal health data as may be 
inconsistent with the guarantees in Article 8 of the Convention. (Case Z. c Finlande of 25 
February 1997, 1997-I, p. 347, § 95).” 
Article 7 of the Charter of Fundamental Rights of the European Union similarly 
confirms the right to privacy while Article 8 establishes the right to the protection of 
personal data. 
The Council of Europe has issued important norms relative to personal data processing. 
Its Convention for the protection of individuals with regard to automatic processing of 
personal data (28 January 1981) (Treaty n° 108) represents a significant source for all 
member states.  
The Council of Europe has also adopted specific recommendations concerning personal 
data processing involved in projects implementing healthgrid technology: 
• Recommendation (83) 10 of the Committee of Ministers on the protection of 
personal data used for scientific research and statistics, adopted on 23 September 
1983. 
• Recommendation (90) 8 of 29 March 1990 on the impact of new technologies on 
health services, particularly primary health care. 
• Recommendation (97) 5 of the Committee of Ministers to Member States on the 
protection of medical data, adopted on 13 February 1997. 
• Convention for the protection of Human Rights and dignity of the human being 
with regard to the application of biology and medicine: Convention on Human 
Rights and Biomedicine (Treaty n° 164) (4 April 1997). 
• Recommendation (97) 18 concerning the protection of personal data collected and 
processed for statistical purposes, adopted on 30 September 1997. 
• Recommendation n° R (99) 5 of the Committee of Members to Member States for 
the protection of privacy on the Internet – Guidelines for the protection of 
individuals with regard to the collection and processing of personal data on 
information highways, adopted on 23 February 1999. 
• Recommendation 2/2001 on certain minimum requirements for collecting personal 
data on-line in the European Union, adopted on 17 May 2001. 
The Council of Europe recommends that specific models designed to ensure 
confidentiality of patient information should be developed in relation to the application of 
information technology to health care systems (cf. R (90) 8 of 29 March 1990, op cit, point 
8 of the Guidelines). 
In the extent of its attributions, the European Union has adopted special norms relative 
to personal data processing, namely: 
• Resolution of the Council and of the Representatives of the Governments of the 
Member States, meeting within the Council, of 29 May 1986, concerning the 
adoption of a European emergency health card. 
• Directive 95/46/EC of the European Parliament and of the Council of 24 October 
1995 on the protection of individuals with regard to the processing of personal data 
and on the free movement of such data. 
• Directive 2002/58/EC of the European Parliament and of the Council of 12 July 
2002 concerning the processing of personal data and the protection of privacy in 
the electronic communications sector (Directive on privacy and electronic 
communications). 
The European Group on Ethics has adopted an important opinion concerning the 
processing of personal data related to health (cf. Opinion of the European Group on Ethics 
in Science and New Technologies to the European Commission, Ethical issues of healthcare 
in the information society, n° 13, 30 July 1999). 
The World Medical Association has issued several documents of interest to some 
healthgrid projects: 
• Declaration on the patient’s rights (World Medical Association Declaration on the 
Rights of the Patient, adopted by the 34th World Medical Assembly Lisbon, 
Portugal, September/October 1981 and amended by the 47th General Assembly 
Bali, Indonesia, September 1995); 
• Guidelines concerning the practice of Telemedicine (World Medical Association 
Statement on Accountability, Responsibilities and Ethical Guidelines in the 
Practice of Telemedicine, adopted by the 51st World Medical Assembly Tel Aviv, 
Israel, October 1999); 
• Declaration on Ethical considerations regarding Health Data Bases (adopted by the 
WMA General Assembly, Washington 2002); 
• Declaration on Ethical Principles for Medical Research involving Human Subjects 
(adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and 
amended by the 29th WMA General Assembly, Tokyo, Japan, October 1975 35th 
WMA General Assembly, Venice, Italy, October 1983 41st WMA General 
Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset 
West, Republic of South Africa, October 1996 and the 52nd WMA General 
Assembly, Edinburgh, Scotland, October 2000 Note of Clarification on Paragraph 
29 added by the WMA General Assembly, Washington 2002). 
National norms on personal data processing must comply with this international 
framework, although a certain margin is generally allowed to member states in their 
implementation. This may cause some disparity in national norms in this matter, adding to 
the existence of national norms for which no international rules exist and upon which 
member states are free to decide. 
In any case it is of prime interest to qualify correctly any operations carried out on 
personal data when using healthgrid technology and to define the role of each person 
involved (health care practitioners, service providers, patient, etc.). 
From a technical viewpoint, PETs (see chapter 8) offer very strong support to the 
security and the confidentiality of the processed personal data. They aim to reduce the 
processing of personal data and to suggest appropriate measures to secure data processing.  
9.3. HEALTHGRID SERVICES’ STATUS 
Some projects aim at providing services to health care professionals or to scientists. 
These services must be qualified according to the norms applicable to ‘information society’ 
services. 
An information society service is any service normally provided for remuneration, at a 
distance, by electronic means and at the individual request of a recipient of services.  
• “At a distance” means that the service is provided without the parties being 
simultaneous present. Services provided in the physical presence of the provider 
and the recipient, even if they involve the use of electronic devices are not 
provided “at a distance”. 
• “By electronic means” means that the service is sent initially and received at its 
destination by means of electronic equipment for the processing (including digital 
compression) and storage of data, and entirely transmitted, conveyed and received 
by wire, by radio, by optical means or by other electromagnetic means. Services 
that are not provided via electronic processing/inventory systems are not services 
provided “by electronic means” (e.g. telephone/fax consultation of a doctor).  
• “At the individual request of a recipient of services” means that the service is 
provided through the transmission of data on individual request.  
Information society services also include services consisting of the transmission of 
information via a communication network, in providing access to a communication network, 
or in hosting information provided by a recipient of the service. 
Activities which by their very nature cannot be carried out at a distance and by 
electronic means, such as medical advice requiring the physical examination of a patient are 
not information society services. 
The taking up and pursuit of the activity of an information society service provider may 
not be made subject to prior authorization or any other requirement having equivalent effect 
(art. 4.1 of D 2000/31/EC of 8 June 2000 on certain legal aspects of information society 
services, in particular electronic commerce, in the Internal Market – Directive on Electronic 
Commerce). The service provider must therefore comply with a number of special rules 
when offering information society services. 
This provision of services may result from a contractual relationship. The latter must be 
analysed on an individual basis in each project. In case of an international situation, when 
providing information society services, one should preliminarily examine what are the 
competent jurisdictions before defining the law applicable to the contractual obligations of 
the parties.  
Several international instruments can be mentioned in this regard: 
• Convention on the law applicable to contractual obligations opened for signature in 
Rome on 19 June 1980 (80/934/EEC). 
• Directive 1999/93/EC of the European Parliament and of the Council of 13 
December 1999 on a Community framework for electronic signatures. 
• Directive 2000/35/EC of the European Parliament and of the Council of 29 June 
2000 on combating late payment in commercial transactions. 
9.4. END-USER’S STATUS 
The use of healthgrid technology by health care professionals raises special questions. 
On one hand, is the end-user legally authorized to use the healthgrid technology? Is the use 
of healthgrid technology permitted in medical practice or in scientific research? The answer 
lies in the rules governing the professional activities of the end-user.  
Concerning some projects, it is useful to remember that the European Union has 
adopted the Directive 2001/20/EC of the European Parliament and of the Council of 4 April 
2001 on the approximation of the laws, regulations and administrative provisions of 
member states relating to the implementation of good clinical practice in the conduct of 
clinical trials on medicinal products for human use. 
On the other hand, in case of medical tele-expertise, medical tele-consultancy, or 
medical tele-assistance, involving healthcare practitioners from different member states, the 
question is to know if the health care practitioner in charge of the patient is legally 
authorized to seek the assistance of a foreign healthcare practitioner, and, if positive, under 
which conditions.  
Simultaneously this foreign healthcare practitioner should also find out whether he is 
legally authorized to provide assistance to a healthcare practitioner located in another 
country. 
Beyond the determination of the persons liable in case of medical accident or fault, one 
must define the status of the health care practitioner participating to the provision of health 
care in another member state, and the status of the healthcare practitioner having asked his 
assistance. This problem is far beyond the simple question of medical qualification 
equivalency. 
In the same way, the cooperation between health care practitioners inside a same 
member state or from different member states raises the very delicate question of the legal 
framework of this cooperation.  
9.5. PATIENT’S STATUS 
Implicitly or explicitly all the healthgrid projects aim to participate in the search for 
medical progress as well as in its preventive and curative aspects. Hence the patient is very 
much at the heart of the implementation of healthgrid technology. 
The Council of Europe is clear on the patient’s interest in his active participation in his 
own treatment (cf. Recommendation R (80) 4).  The legal qualification of the parties 
involved in the processing of the patient’s personal data, including the place of the patient, 
is likely to highlight some tensions underlying the medical relationship. 
9.6. LIABILITY ISSUES 
The question of the determination of the persons liable in case of medical accident or 
fault relative to the use of healthgrid technology when providing health care to a patient is 
crucial but delicate. In case of an international situation, the question is far more complex. 
With respect to this, one should take into account several factors which are not necessarily 
likely to be under complete control. 
The first element of uncertainty results from the determination of the possible 
jurisdictions likely to recognize the case. With respect to this, the European Union has 
recently adopted the Council Regulation (EC) No 44/2001 of 22 December 2000 on 
jurisdiction and the recognition and enforcement of judgments in civil and commercial 
matters. The determination of the jurisdiction will permit to determine the law applicable to 
the case.  
The European Union has adopted some norms relative to the matter of liability: 
• European Convention on Products Liability in regard to Personal Injury and Death 
(Council of Europe, Treaty n° 91, adopted on 27 January 1977); 
• European Directive 85/374/EEC of 25 July 1985 on the approximation of the laws, 
regulations and administrative provisions of the member states concerning liability 
for defective products.  
It has to be remembered that the European Union has also adopted special rules 
concerning the resolution of disputes: 
• Council Decision 2001/470/EC of 28 May 2001 establishing a European Judicial 
Network in civil and commercial matters. Its objectives are to improve effective 
judicial cooperation between member states and effective access to justice for 
persons engaging in cross-border litigation; 
• Council Regulation (EC) No 1206/2001 of 28 May 2001 on cooperation between 
the courts of the member states in the taking of evidence in civil or commercial 
matters. 
Mention should also be made of alternative dispute resolution and on-line dispute 
resolution.  
9.7. IPR AND COMPETITION ISSUES 
The creation and the use of healthgrid technologies may raise important Intellectual 
Property Rights (IPR) questions. Indeed, healthgrid technologies are sometimes created like 
patchworks. This poses the question of the IPR relative to the constitutive elements of the 
‘patchwork’ under consideration. 
The European Union has adopted several Directives concerning IPR issues: 
• Council Directive 91/250/EEC of 14 May 1991 on the legal protection of computer 
programs; 
• Council Directive 92/100/EEC of 19 November 1992 on rental right and lending 
right and on certain rights related to copyright in the field of intellectual property 
• Council Directive 93/98/EEC of 29 October 1993 harmonizing the term of 
protection of copyright and certain related rights; 
• Directive 96/9/EC of the European Parliament and of the Council of 11 March 
1996 on the legal protection of databases; 
• Directive 2001/29/EC of the European Parliament and of the Council of 22 May 
2001 on the harmonisation of certain aspects of copyright and related rights in the 
information society; 
Usually projects aiming at implementing healthgrid technology bring together several 
partners into consortium. Their behaviour also has to comply with competition law 
(Monopolistic positions, abuse of dominant position, concerted practices). 
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